<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>RIZATRIPTAN BENZOATE - rizatriptan benzoate tablet, orally disintegrating </strong><br>Macleods Pharmaceuticals Limited<br></p></div>
<div id="Highlights" class="Highlights"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1>HIGHLIGHTS OF PRESCRIBING INFORMATION</h1>
<div class="HighlightsDisclaimer">These highlights do not include all the information needed to use rizatriptan benzoate orally disintegrating tablets safely and effectively. <br>See full prescribing information for rizatriptan benzoate orally disintegrating tablets.<br>Rizatriptan Benzoate Orally Disintegrating Tablets, for oral use <br>Initial U.S. Approval: 1998<br>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>RECENT MAJOR CHANGES</span></h1>
<div><p class="Highlighta">Indications and Usage <br>Acute Treatment of <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">Migraine</span> (1)   12/2011 </p></div>
</div>
<div></div>
<div class="HighlightSection">
<h1 class="Highlights"><span>INDICATIONS AND USAGE</span></h1>
<div>
<p class="Highlighta">Rizatriptan benzoate is a serotonin (5-HT)<span class="Sub">1B/1D</span> receptor agonist (triptan) indicated for the acute treatment of <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraine</span> with or without <span class="product-label-link" type="condition" conceptid="4091160" conceptname="Aura">aura</span> in adults and in pediatric patients 6 to 17 years of age (1)  (<a href="#section-1">1</a>)</p>
<p class="Highlighta">Limitations of Use:<br>• Use only after clear diagnosis of <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraine</span> has been established (1)<br>• Not indicated for the <span class="product-label-link" type="condition" conceptid="4118659" conceptname="Prophylactic">prophylactic</span> therapy of <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraine</span> (1)<br>• Not indicated for the treatment of <span class="product-label-link" type="condition" conceptid="381278" conceptname="Cluster headache">cluster headache</span> (1)  (<a href="#section-1">1</a>)</p>
<br>
</div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE AND ADMINISTRATION</span></h1>
<div>
<p class="Highlighta">• Adults: 5 mg or 10 mg single dose; separate repeat doses by at least 2 hours; maximum dose in a 24-hour period: 30 mg (2.1) <br>• Adjust dose if coadministered with propranolol (2.4)  (<a href="#section-2">2</a>)</p>
<br>
</div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE FORMS AND STRENGTHS</span></h1>
<div><p class="Highlighta">• Rizatriptan Benzoate Orally Disintegrating Tablets: 5 mg and 10 mg (3)  (<a href="#section-3">3</a>)</p></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>CONTRAINDICATIONS</span></h1>
<div>
<p class="Highlighta">• History of <span class="product-label-link" type="condition" conceptid="4124683" conceptname="Silent myocardial ischemia">ischemic heart disease</span> or coronary artery <span class="product-label-link" type="condition" conceptid="4215494" conceptname="Vasospasm">vasospasm</span> (4)<br>• History of <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span> or transient ischemic attack (4)<br>• <span class="product-label-link" type="condition" conceptid="321052" conceptname="Peripheral vascular disease">Peripheral vascular disease</span> (4)<br>• Ischemic bowel disease (4)<br>• <span class="product-label-link" type="condition" conceptid="4269635" conceptname="Hypertensive episode">Uncontrolled hypertension</span> (4)<br>• Recent (within 24 hours) use of another 5-HT<span class="Sub">1</span> agonist (e.g., another triptan), or of an ergotamine-containing medication (4) <br>• Hemiplegic or basilar <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraine</span> (4) <br>• MAO-A inhibitor used in the past 2 weeks (4) <br>• <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity</span> to rizatriptan benzoate (4)  (<a href="#section-4">4</a>)</p>
<br>
</div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>WARNINGS AND PRECAUTIONS</span></h1>
<div>
<p class="Highlighta">• <span class="product-label-link" type="condition" conceptid="4124683" conceptname="Silent myocardial ischemia">Myocardial Ischemia</span>, <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">Myocardial Infarction</span>, and Prinzmetal's Angina: Perform cardiac evaluation in patients with multiple cardiovascular risk factors (5.1)<br>• <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">Arrhythmias</span>: Discontinue dosing if occurs (5.2)<br>• Chest/throat/neck/<span class="product-label-link" type="condition" conceptid="4168686" conceptname="Jaw pain">jaw pain</span>, tightness, pressure, or heaviness; Generally not associated with <span class="product-label-link" type="condition" conceptid="4124683" conceptname="Silent myocardial ischemia">myocardial ischemia</span>; Evaluate patients at high risk (5.3)<br>• <span class="product-label-link" type="condition" conceptid="376713" conceptname="Cerebral hemorrhage">Cerebral hemorrhage</span>, <span class="product-label-link" type="condition" conceptid="432923" conceptname="Subarachnoid hemorrhage">subarachnoid hemorrhage</span>, and <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span>: Discontinue dosing if occurs (5.4) <br>• Gastrointestinal ischemic events, peripheral vasospastic reactions: Discontinue dosing if occurs (5.5) <br>• Medication Overuse <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headache</span>: Detoxification may be necessary (5.6) <br>• <span class="product-label-link" type="condition" conceptid="4154707" conceptname="Serotonin syndrome">Serotonin Syndrome</span>: Discontinue dosing if occurs (5.7)  (<a href="#section-5">5</a>)</p>
<br>
</div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>ADVERSE REACTIONS</span></h1>
<div>
<p class="Highlighta">The most common adverse reactions in adults were (incidence ≥ 5% and greater than placebo): <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">asthenia</span>/<span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span>, <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">somnolence</span>, <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>/pressure sensation and <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span> (6.1) </p>
<p class="Highlighta"><span class="Bold">To report SUSPECTED ADVERSE REACTIONS, contact Macleods Pharma USA, Inc. at 1-888-943-3210 or  FDA at 1-800-FDA-1088 or </span><span class="Bold"><a href="http://www.fda.gov/medwatch">www.fda.gov/medwatch</a></span><span class="Bold">.<br></span> </p>
</div>
<div></div>
<div></div>
</div>
<div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>USE IN SPECIFIC POPULATIONS</span></h1>
<div>
<p class="Highlighta">• Pregnancy: Based on animal data, may cause fetal harm (8.1) <br>• Phenylketonurics: Rizatriptan benzoate orally disintegrating tablets  contain phenylalanine (8.6)   (<a href="#section-8">8</a>)</p>
<br><br><br><p class="Highlighta"><span class="Italics">Information describing the use and dosing of rizatriptan benzoate in pediatric patients (6 to 17 years old) is approved for Merck &amp; Co., Inc.'s Rizatriptan Benzoate Tablets. However, due to Merck &amp; Co., Inc.'s marketing exclusivity rights, this drug product is not labeled for pediatric use.</span>  (<a href="#section-8">8</a>)</p>
<p class="Highlighta"><span class="Italics"> </span>  (<a href="#section-8">8</a>)</p>
<br>
</div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div></div>
<div></div>
<div>
<div></div>
<div></div>
</div>
<div><div></div></div>
<div>
<div></div>
<div></div>
</div>
<div></div>
<div><div></div></div>
<div></div>
<div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<p class="HighlightsSeeReference">See 17 for PATIENT COUNSELING INFORMATION.</p>
<p class="HighlightsRevision">Revised: 7/2015</p>
</div></td></tr></table></div>
<div id="Index" class="Index"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1 class="Colspan">FULL PRESCRIBING INFORMATION: CONTENTS<a href="#footnote-content" name="footnote-reference-content">*</a>
</h1>
<h1><a href="#section-1" class="toc">1 INDICATIONS &amp; USAGE</a></h1>
<h1><a href="#section-2" class="toc">2 DOSAGE &amp; ADMINISTRATION</a></h1>
<h2><a href="#section-2.1" class="toc">2.1 Dosing Information in Adults</a></h2>
<h2><a href="#section-2.2" class="toc">2.2 Dosing Information in Pediatric Patients (Age 6 to 17 Years)</a></h2>
<h2><a href="#section-2.3" class="toc">2.3 Administration of Rizatriptan Benzoate Orally Disintegrating Tablets</a></h2>
<h2><a href="#section-2.4" class="toc">2.4 Dosage Adjustment for Patients on Propranolol</a></h2>
<h1><a href="#section-3" class="toc">3 DOSAGE FORMS AND STRENGTHS</a></h1>
<h1><a href="#section-4" class="toc">4 CONTRAINDICATIONS</a></h1>
<h1><a href="#section-5" class="toc">5 WARNINGS AND PRECAUTIONS</a></h1>
<h2><a href="#section-5.1" class="toc">5.1 <span class="product-label-link" type="condition" conceptid="4124683" conceptname="Silent myocardial ischemia">Myocardial Ischemia</span>, <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">Myocardial Infarction</span>, and Prinzmetal's Angina</a></h2>
<h2><a href="#section-5.2" class="toc">5.2 <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">Arrhythmias</span></a></h2>
<h2><a href="#section-5.3" class="toc">5.3 Chest, Throat, Neck and/or <span class="product-label-link" type="condition" conceptid="4168686" conceptname="Jaw pain">Jaw Pain</span>/Tightness/Pressure</a></h2>
<h2><a href="#section-5.4" class="toc">5.4 Cerebrovascular Events</a></h2>
<h2><a href="#section-5.5" class="toc">5.5 Other <span class="product-label-link" type="condition" conceptid="4215494" conceptname="Vasospasm">Vasospasm</span> Reactions</a></h2>
<h2><a href="#section-5.6" class="toc">5.6 Medication Overuse <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headache</span></a></h2>
<h2><a href="#section-5.7" class="toc">5.7 <span class="product-label-link" type="condition" conceptid="4154707" conceptname="Serotonin syndrome">Serotonin Syndrome</span></a></h2>
<h2><a href="#section-5.8" class="toc">5.8 Increase in Blood Pressure</a></h2>
<h1><a href="#section-6" class="toc">6 ADVERSE REACTIONS</a></h1>
<h2><a href="#section-6.1" class="toc">6.1 Clinical Trials Experience</a></h2>
<h2><a href="#section-6.2" class="toc">6.2 Post-marketing Experience</a></h2>
<h1><a href="#section-7" class="toc">7 DRUG INTERACTIONS</a></h1>
<h2><a href="#section-7.1" class="toc">7.1 Propranolol</a></h2>
<h2><a href="#section-7.2" class="toc">7.2 Ergot-containing Drugs</a></h2>
<h2><a href="#section-7.3" class="toc">7.3 Other 5-HT1 Agonists</a></h2>
<h2><a href="#section-7.4" class="toc">7.4 SSRIs/SNRIs and <span class="product-label-link" type="condition" conceptid="4154707" conceptname="Serotonin syndrome">Serotonin Syndrome</span></a></h2>
<h2><a href="#section-7.5" class="toc">7.5 Monoamine Oxidase Inhibitors</a></h2>
<h1><a href="#section-8" class="toc">8 USE IN SPECIFIC POPULATIONS</a></h1>
<h2><a href="#section-8.1" class="toc">8.1 Pregnancy</a></h2>
<h2><a href="#section-8.2" class="toc">8.3 Nursing Mothers</a></h2>
<h2><a href="#section-8.3" class="toc">8.4 Pediatric Use</a></h2>
<h2><a href="#section-8.4" class="toc">8.5 Geriatric Use</a></h2>
<h2><a href="#section-8.5" class="toc">8.6 Patients with <span class="product-label-link" type="condition" conceptid="432872" conceptname="Phenylketonuria">Phenylketonuria</span></a></h2>
<h1><a href="#section-9" class="toc">10 OVERDOSAGE</a></h1>
<h1><a href="#section-10" class="toc">11 DESCRIPTION</a></h1>
<h1><a href="#section-11" class="toc">12 CLINICAL PHARMACOLOGY</a></h1>
<h2><a href="#section-11.1" class="toc">12.1 Mechanism of Action</a></h2>
<h2><a href="#section-11.2" class="toc">12.3 Pharmacokinetics</a></h2>
<h1><a href="#section-12" class="toc">13 NONCLINICAL TOXICOLOGY</a></h1>
<h2><a href="#section-12.1" class="toc">13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</a></h2>
<h1><a href="#section-13" class="toc">14 CLINICAL STUDIES</a></h1>
<h2><a href="#section-13.1" class="toc">14.1 Adults</a></h2>
<h2><a href="#section-13.2" class="toc">14.2 Pediatric Patients 6 to 17 Years of Age</a></h2>
<h1><a href="#section-14" class="toc">16 HOW SUPPLIED/STORAGE AND HANDLING</a></h1>
<h1><a href="#section-15" class="toc">17 PATIENT COUNSELING INFORMATION</a></h1>
<dl class="Footnote">
<dt><a href="#footnote-reference-content" name="footnote-content">*</a></dt>
<dd>Sections or subsections omitted from the full prescribing information are not listed.</dd>
</dl>
</div></td></tr></table></div>
<div class="Contents">
<h1>FULL PRESCRIBING INFORMATION</h1>
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="Section_1"></a><a name="section-1"></a><p></p>
<h1>1 INDICATIONS &amp; USAGE</h1>
<p class="First" style="border-left:1px solid;"><span class="XmChange">Rizatriptan benzoate orally disintegrating tablets are indicated for the acute treatment of <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraine</span> with or without <span class="product-label-link" type="condition" conceptid="4091160" conceptname="Aura">aura</span> in adults and in pediatric patients 6 to 17 years </span>old.</p>
<br><p><span class="Italics">Information related to usage of rizatriptan benzoate in pediatric patients (6 to 17 years old) is approved for Merck &amp; Co., Inc.'s Rizatriptan Benzoate Orally Disintegrating Tablets. However, due to Merck &amp; Co., Inc.'s marketing exclusivity rights, this drug product is not labeled with that pediatric patient (6 to 17 years old) usage information.<br></span></p>
<p><span class="Underline">Limitations of Use</span>: <br>• Rizatriptan benzoate orally disintegrating tablets should only be used where a clear diagnosis of <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraine</span> has been established. If a patient has no response for the first <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraine</span> attack treated with rizatriptan benzoate orally disintegrating tablets, the diagnosis of <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraine</span> should be reconsidered before rizatriptan benzoate tablets are administered to treat any subsequent attacks. <br>• Rizatriptan benzoate orally disintegrating tablets are not indicated for use in the management of hemiplegic or basilar <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraine</span> <span class="Italics">[see Contraindications (<a href="#Section_4">4</a>)]. <br></span>• Rizatriptan benzoate orally disintegrating tablets are not indicated for the prevention of <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraine</span> attacks. <br>• Safety and effectiveness of rizatriptan benzoate orally disintegrating tablets have not been established for <span class="product-label-link" type="condition" conceptid="381278" conceptname="Cluster headache">cluster headache</span>.</p>
<br>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="Section_2"></a><a name="section-2"></a><p></p>
<h1>2 DOSAGE &amp; ADMINISTRATION</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_2.2"></a><a name="section-2.1"></a><p></p>
<h2>2.1 Dosing Information in Adults</h2>
<p class="First">The recommended starting dose of rizatriptan benzoate orally disintegrating tablets is either 5 mg or 10 mg for the acute treatment of <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraines</span> in adults. The 10 mg dose may provide a greater effect than the 5 mg dose, but may have a greater risk of adverse reactions <span class="Italics">[see Clinical Studies (<a href="#Section_14.1">14.1</a>)]. </span></p>
<p><span class="Bold"><span class="Italics">Redosing in Adults:</span></span> Although the effectiveness of a second dose or subsequent doses has not been established in placebo-controlled trials, if the <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraine headache</span> returns, a second dose may be administered 2 hours after the first dose. The maximum daily dose should not exceed 30 mg in any 24-hour period. The safety of treating, on average, more than four <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headaches</span> in a 30-day period has not been established.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_2.3"></a><a name="section-2.2"></a><p></p>
<h2>2.2 Dosing Information in Pediatric Patients (Age 6 to 17 Years)</h2>
<p class="First" style="border-left:1px solid;"><span class="Italics" style="border-left:1px solid;"><span class="XmChange"><span class="Italics">Information related to  usage of rizatriptan benzoate in pediatric patients (6 to 17 years old) is approved for Merck &amp; Co., Inc.'s Rizatriptan Benzoate Orally Disintegrating Tablets. However, due to Merck &amp; Co., Inc.'s marketing exclusivity rights, this drug product is not labeled with that  pediatric patient (6 to 17 years old</span></span>) usage information.</span></p>
<p><span class="Italics"> </span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_2.4"></a><a name="section-2.3"></a><p></p>
<h2>2.3 Administration of Rizatriptan Benzoate Orally Disintegrating Tablets</h2>
<p class="First">For rizatriptan benzoate orally disintegrating tablets, administration with liquid is not necessary. Orally disintegrating tablets are packaged in a <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">blister</span> within a carton and patients should not remove the <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">blister</span> from the carton until just prior to dosing. The <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">blister</span> pack should then be peeled open with dry hands and the orally disintegrating tablet placed on the tongue, where it will dissolve and be swallowed with the saliva.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_2.5"></a><a name="section-2.4"></a><p></p>
<h2>2.4 Dosage Adjustment for Patients on Propranolol</h2>
<p class="First"><span class="Bold"><span class="Italics">Adult Patients:</span></span> In adult patients taking propranolol, only the 5 mg dose of rizatriptan benzoate orally disintegrating tablets is recommended, up to a maximum of three doses in any 24-hour period (15 mg)<span class="Italics"> [see Drug Interactions (<a href="#Section_7.1">7.1</a>) and Clinical Pharmacology (<a href="#Section_12.3">12.3</a>)].<br></span></p>
<p><span class="Italics"><span class="Bold">Pediatric Patients: </span>Dosage adjustment information of rizatriptan benzoate for pediatric patients (6 to 17 years old) taking propranolol is approved for Merck &amp; Co., Inc.'s Rizatriptan Benzoate Orally Disintegrating Tablets. However, due to Merck &amp; Co., Inc.'s marketing exclusivity rights, this drug product is not labeled with that dosage adjustment information.</span></p>
</div>
</div>
<div class="Section" data-sectionCode="43678-2">
<a name="Section_3"></a><a name="section-3"></a><p></p>
<h1>3 DOSAGE FORMS AND STRENGTHS</h1>
<p class="First"><span class="Bold"><span class="Italics">Rizatriptan Benzoate Orally Disintegrating Tablets:<br></span></span>• The 5 mg tablets are white to off-white, round shaped uncoated tablets debossed with 'L58' on one side and plain on other side.<br>• The 10 mg tablets are white to off-white, round shaped uncoated tablets debossed with 'L 59' on one side and plain on other side.</p>
<br>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="Section_4"></a><a name="section-4"></a><p></p>
<h1>4 CONTRAINDICATIONS</h1>
<p class="First">Rizatriptan benzoate orally disintegrating tablets are contraindicated in patients with:<br>• Ischemic <span class="product-label-link" type="condition" conceptid="317576" conceptname="Coronary arteriosclerosis">coronary artery disease</span> (<span class="product-label-link" type="condition" conceptid="321318" conceptname="Angina pectoris">angina pectoris</span>, history of <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span>, or documented silent <span class="product-label-link" type="condition" conceptid="4200991" conceptname="Ischemia">ischemia</span>), or other significant underlying cardiovascular disease <span class="Italics">[see Warnings and Precautions (<a href="#Section_5.1">5.1</a>)].<br></span>• Coronary artery <span class="product-label-link" type="condition" conceptid="4215494" conceptname="Vasospasm">vasospasm</span> including Prinzmetal's angina <span class="Italics">[see Warnings and Precautions (<a href="#Section_5.1">5.1</a>)].<br></span>• History of <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span> or transient ischemic attack (TIA)<span class="Italics"> [see Warnings and Precautions (<a href="#Section_5.4">5.4</a>)].<br></span>• <span class="product-label-link" type="condition" conceptid="321052" conceptname="Peripheral vascular disease">Peripheral vascular disease</span> (PVD)<span class="Italics"> [see Warnings and Precautions (<a href="#Section_5.5">5.5</a>)].<br></span>• Ischemic bowel disease <span class="Italics">[see Warnings and Precautions (<a href="#Section_5.5">5.5</a>)].<br></span>• <span class="product-label-link" type="condition" conceptid="4269635" conceptname="Hypertensive episode">Uncontrolled hypertension</span> <span class="Italics">[see Warnings and Precautions (<a href="#Section_5.9">5.8</a>)].<br></span>• Recent use (i.e., within 24 hours) of another 5-HT<span class="Sub">1</span> agonist, ergotamine-containing medication, or ergot-type medication (such as dihydroergotamine or methysergide)<span class="Italics"> [see Drug Interactions (<a href="#Section_7.2">7.2</a> and <a href="#Section_7.3">7.3</a>)]. <br></span>• Hemiplegic or basilar <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraine</span>. <br>• Concurrent administration or recent discontinuation (i.e., within 2 weeks) of a MAO-A inhibitor <span class="Italics">[see Drug Interactions (<a href="#Section_7.5">7.5</a>) and Clinical Pharmacology (<a href="#Section_12.3">12.3</a>)].</span><br>• <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity</span> to rizatriptan benzoate orally disintegrating tablets (<span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">angioedema</span> and <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylaxis</span> seen) <span class="Italics">[see Adverse Reactions (<a href="#Section_6.2">6.2</a>)].</span></p>
<br>
</div>
<div class="Section" data-sectionCode="43685-7">
<a name="Section_5"></a><a name="section-5"></a><p></p>
<h1>5 WARNINGS AND PRECAUTIONS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_5.1"></a><a name="section-5.1"></a><p></p>
<h2>5.1 <span class="product-label-link" type="condition" conceptid="4124683" conceptname="Silent myocardial ischemia">Myocardial Ischemia</span>, <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">Myocardial Infarction</span>, and Prinzmetal's Angina</h2>
<p class="First">Rizatriptan benzoate should not be given to patients with ischemic or vasospastic <span class="product-label-link" type="condition" conceptid="317576" conceptname="Coronary arteriosclerosis">coronary artery disease</span>. There have been rare reports of serious cardiac adverse reactions, including <span class="product-label-link" type="condition" conceptid="312327" conceptname="Acute myocardial infarction">acute myocardial infarction</span>, occurring within a few hours following administration of rizatriptan benzoate. Some of these reactions occurred in patients without known <span class="product-label-link" type="condition" conceptid="317576" conceptname="Coronary arteriosclerosis">coronary artery disease</span> (CAD). 5-HT<span class="Sub">1</span> agonists including rizatriptan benzoate may cause coronary artery <span class="product-label-link" type="condition" conceptid="4215494" conceptname="Vasospasm">vasospasm</span> (Prinzmetal's Angina), even in patients without a history of CAD.</p>
<p>Triptan-naïve patients who have multiple cardiovascular risk factors (e.g., increased age, <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span>, <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>, smoking, <span class="product-label-link" type="condition" conceptid="433736" conceptname="Obesity">obesity</span>, strong family history of CAD) should have a cardiovascular evaluation prior to receiving rizatriptan benzoate. If there is evidence of CAD or coronary artery <span class="product-label-link" type="condition" conceptid="4215494" conceptname="Vasospasm">vasospasm</span>, rizatriptan benzoate should not be administered <span class="Italics">[see Contraindications (<a href="#Section_4">4</a>)]</span>. For patients who have a negative cardiovascular evaluation, consideration should be given to administration of the first rizatriptan benzoate dose in a medically-supervised setting and performing an electrocardiogram (ECG) immediately following rizatriptan benzoate administration. Periodic cardiovascular evaluation should be considered in intermittent long-term users of rizatriptan benzoate who have cardiovascular risk factors.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_5.2"></a><a name="section-5.2"></a><p></p>
<h2>5.2 <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">Arrhythmias</span></h2>
<p class="First">Life threatening disturbances of cardiac rhythm, including <span class="product-label-link" type="condition" conceptid="4103295" conceptname="Ventricular tachycardia">ventricular tachycardia</span> and <span class="product-label-link" type="condition" conceptid="437894" conceptname="Ventricular fibrillation">ventricular fibrillation</span> leading to <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>, have been reported within a few hours following the administration of 5-HT<span class="Sub">1</span> agonists. Discontinue rizatriptan benzoate if these disturbances occur.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_5.3"></a><a name="section-5.3"></a><p></p>
<h2>5.3 Chest, Throat, Neck and/or <span class="product-label-link" type="condition" conceptid="4168686" conceptname="Jaw pain">Jaw Pain</span>/Tightness/Pressure</h2>
<p class="First">As with other 5-HT<span class="Sub">1</span> agonists, sensations of tightness, <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>, pressure, and heaviness in the precordium, throat, neck and jaw commonly occur after treatment with rizatriptan benzoate and are usually non-cardiac in origin. However, if a cardiac origin is suspected, patients should be evaluated. Patients shown to have CAD and those with Prinzmetal's <span class="product-label-link" type="condition" conceptid="315830" conceptname="Prinzmetal angina">variant angina</span> should not receive 5-HT<span class="Sub">1</span> agonists.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_5.4"></a><a name="section-5.4"></a><p></p>
<h2>5.4 Cerebrovascular Events</h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="376713" conceptname="Cerebral hemorrhage">Cerebral hemorrhage</span>, <span class="product-label-link" type="condition" conceptid="432923" conceptname="Subarachnoid hemorrhage">subarachnoid hemorrhage</span>, and <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span> have occurred in patients treated with 5-HT<span class="Sub">1</span> agonists, and some have resulted in fatalities. In a number of cases, it appears possible that the cerebrovascular events were primary, the 5-HT<span class="Sub">1</span> agonist having been administered in the incorrect belief that the symptoms experienced were a consequence of <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraine</span>, when they were not. Also, patients with <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraine</span> may be at increased risk of certain cerebrovascular events (e.g., <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span>, <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">hemorrhage</span>, transient ischemic attack). Discontinue rizatriptan benzoate if a cerebrovascular event occurs.</p>
<p>As with other <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">acute migraine</span> therapies, before treating <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headaches</span> in patients not previously diagnosed as migraineurs, and in migraineurs who present with atypical symptoms, care should be taken to exclude other potentially serious neurological conditions. Rizatriptan benzoate should not be administered to patients with a history of <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span> or transient ischemic attack <span class="Italics">[see Contraindications (<a href="#Section_4">4</a>)].<br></span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_5.5"></a><a name="section-5.5"></a><p></p>
<h2>5.5 Other <span class="product-label-link" type="condition" conceptid="4215494" conceptname="Vasospasm">Vasospasm</span> Reactions</h2>
<p class="First">5-HT<span class="Sub">1</span> agonists, including rizatriptan benzoate, may cause non-coronary vasospastic reactions, such as peripheral vascular <span class="product-label-link" type="condition" conceptid="4200991" conceptname="Ischemia">ischemia</span>, gastrointestinal vascular <span class="product-label-link" type="condition" conceptid="4200991" conceptname="Ischemia">ischemia</span> and <span class="product-label-link" type="condition" conceptid="4206471" conceptname="Infarct">infarction</span> (presenting with <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span> and <span class="product-label-link" type="condition" conceptid="4318833" conceptname="Hemorrhagic diarrhea">bloody diarrhea</span>), <span class="product-label-link" type="condition" conceptid="4044745" conceptname="Splenic infarction">splenic infarction</span>, and Raynaud's syndrome. In patients who experience symptoms or signs suggestive of non-<span class="product-label-link" type="condition" conceptid="4127089" conceptname="Coronary artery spasm">coronary vasospasm</span> reaction following the use of any 5-HT<span class="Sub">1</span> agonist, the suspected <span class="product-label-link" type="condition" conceptid="4215494" conceptname="Vasospasm">vasospasm</span> reaction should be ruled out before receiving additional rizatriptan benzoate doses.</p>
<p>Reports of transient and permanent <span class="product-label-link" type="condition" conceptid="377551" conceptname="Blind hypertensive eye">blindness</span> and significant partial <span class="product-label-link" type="condition" conceptid="377551" conceptname="Blind hypertensive eye">vision loss</span> have been reported with the use of 5-HT<span class="Sub">1</span> agonists. Since visual disorders may be part of a <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraine</span> attack, a causal relationship between these events and the use of 5-HT<span class="Sub">1</span> agonists have not been clearly established.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_5.6"></a><a name="section-5.6"></a><p></p>
<h2>5.6 Medication Overuse <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headache</span></h2>
<p class="First">Overuse of <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">acute migraine</span> drugs (e.g., ergotamine, triptans, opioids, or a combination of drugs for 10 or more days per month) may lead to exacerbation of <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span> (medication overuse <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>). Medication overuse <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span> may present as <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraine</span>-like daily <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headaches</span>, or as a marked increase in frequency of <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraine</span> attacks. Detoxification of patients, including withdrawal of the overused drugs, and treatment of withdrawal symptoms (which often includes a transient worsening of <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>) may be necessary.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_5.7"></a><a name="section-5.7"></a><p></p>
<h2>5.7 <span class="product-label-link" type="condition" conceptid="4154707" conceptname="Serotonin syndrome">Serotonin Syndrome</span></h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="4154707" conceptname="Serotonin syndrome">Serotonin syndrome</span> may occur with triptans, including rizatriptan benzoate particularly during coadministration with selective serotonin reuptake inhibitors (SSRIs), serotonin norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), and MAO inhibitors <span class="Italics">[see Drug Interactions (<a href="#Section_7.5">7.5</a>)].</span> <span class="product-label-link" type="condition" conceptid="4154707" conceptname="Serotonin syndrome">Serotonin syndrome</span> symptoms may include <span class="product-label-link" type="condition" conceptid="436222" conceptname="Altered mental status">mental status changes</span> (e.g., <span class="product-label-link" type="condition" conceptid="436087" conceptname="Excitement">agitation</span>, <span class="product-label-link" type="condition" conceptid="433031" conceptname="Hallucinations">hallucinations</span>, <span class="product-label-link" type="condition" conceptid="380834" conceptname="Coma">coma</span>), <span class="product-label-link" type="condition" conceptid="434633" conceptname="Disorder of autonomic nervous system">autonomic instability</span> (e.g., <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">tachycardia</span>, <span class="product-label-link" type="condition" conceptid="4354255" conceptname="Labile blood pressure">labile blood pressure</span>, <span class="product-label-link" type="condition" conceptid="4178904" conceptname="Body temperature above reference range">hyperthermia</span>), neuromuscular aberrations (e.g., <span class="product-label-link" type="condition" conceptid="4313132" conceptname="Hyperreflexia">hyperreflexia</span>, <span class="product-label-link" type="condition" conceptid="441417" conceptname="Incoordination">incoordination</span>) and/or <span class="product-label-link" type="condition" conceptid="4302537" conceptname="Digestive system finding">gastrointestinal symptoms</span> (e.g., <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>). The onset of symptoms can occur within minutes to hours of receiving a new or a greater dose of a serotonergic medication. Rizatriptan benzoate treatment should be discontinued if <span class="product-label-link" type="condition" conceptid="4154707" conceptname="Serotonin syndrome">serotonin syndrome</span> is suspected <span class="Italics">[see Drug Interactions (<a href="#Section_7.4">7.4</a>) and Patient Counseling Information (<a href="#Section_16">17</a>)].</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_5.9"></a><a name="section-5.8"></a><p></p>
<h2>5.8 Increase in Blood Pressure</h2>
<p class="First">Significant elevation in blood pressure, including <span class="product-label-link" type="condition" conceptid="312938" conceptname="Hypertensive encephalopathy">hypertensive crisis</span> with acute impairment of organ systems, has been reported on rare occasions in patients with and without a history of <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span> receiving 5-HT<span class="Sub">1</span> agonists, including rizatriptan benzoate. In healthy young adult male and female patients who received maximal doses of rizatriptan benzoate (10 mg every 2 hours for three doses), slight increases in blood pressure (approximately 2-3 mmHg) were observed. Rizatriptan benzoate is contraindicated in patients with <span class="product-label-link" type="condition" conceptid="4269635" conceptname="Hypertensive episode">uncontrolled hypertension</span> <span class="Italics">[see Contraindications (<a href="#Section_4">4</a>)].<br></span></p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="Section_6"></a><a name="section-6"></a><p></p>
<h1>6 ADVERSE REACTIONS</h1>
<p class="First">The following adverse reactions are discussed in more detail in other sections of the labeling:<br>• <span class="product-label-link" type="condition" conceptid="4124683" conceptname="Silent myocardial ischemia">Myocardial Ischemia</span>, <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">Myocardial Infarction</span>, and Prinzmetal's Angina <span class="Italics">[see Warnings and Precautions (<a href="#Section_5.1">5.1</a>)].<br></span>• <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">Arrhythmias</span> <span class="Italics">[see Warnings and Precautions (<a href="#Section_5.2">5.2</a>)].<br></span>• Chest and or Throat, Neck and/or <span class="product-label-link" type="condition" conceptid="4168686" conceptname="Jaw pain">Jaw Pain</span>/Tightness/Pressure <span class="Italics">[see Warnings and Precautions (<a href="#Section_5.3">5.3</a>)].<br></span>• Cerebrovascular Events <span class="Italics">[see Warnings and Precautions (<a href="#Section_5.4">5.4</a>)].<br></span>• Other <span class="product-label-link" type="condition" conceptid="4215494" conceptname="Vasospasm">Vasospasm</span> Reactions <span class="Italics">[see Warnings and Precautions (<a href="#Section_5.5">5.5</a>)].<br></span>• Medication Overuse <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headache</span> <span class="Italics">[see Warnings and Precautions (<a href="#Section_5.6">5.6</a>)].<br></span>• <span class="product-label-link" type="condition" conceptid="4154707" conceptname="Serotonin syndrome">Serotonin Syndrome</span> <span class="Italics">[see Warnings and Precautions (<a href="#Section_5.7">5.7</a>)].<br></span>• Increase in Blood Pressure <span class="Italics">[see Warnings and Precautions (<a href="#Section_5.9">5.8</a>)].<br></span></p>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_6.1"></a><a name="section-6.1"></a><p></p>
<h2>6.1 Clinical Trials Experience</h2>
<p class="First">Because clinical studies are conducted under widely varying conditions, adverse reaction rates observed in the clinical studies of a drug cannot be directly compared to rates in the clinical studies of another drug and may not reflect the rates observed in practice.</p>
<p><span class="Italics"><span class="Bold">Adults:</span> Incidence in Controlled Clinical Trials:</span> Adverse reactions to rizatriptan benzoate were assessed in controlled clinical trials that included over 3,700 adult patients who received single or multiple doses of rizatriptan benzoate tablets. The most common adverse reactions during treatment with rizatriptan benzoate (≥ 5% in either treatment group and greater than placebo) were <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">asthenia</span>/<span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span>, <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">somnolence</span>, <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>/pressure sensation and <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>. These adverse reactions appeared to be dose related.</p>
<p>Table 1 lists the adverse reactions (incidence ≥ 2% and greater than placebo) after a single dose of rizatriptan benzoate in adults.<br><br></p>
<br><br><table border="0" cellpadding="0" cellspacing="0" width="border-collapse: collapse"><tbody class="Headless">
<tr class="Botrule First">
<td class="Lrule Rrule" valign="top">
<span class="Bold">Table 1:</span><br>
</td>
<td class="Rrule" colspan="4" valign="top">
<span class="Bold">Incidence (</span><span class="Bold">³ 2% and Greater than Placebo) of Adverse Reactions After a Single Dose of Rizatriptan Benzoate Tablets or Placebo in Adults</span><br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" colspan="2" rowspan="2" valign="top">
<span class="Bold">Adverse Reactions</span><br>
</td>
<td class="Rrule" align="center" colspan="3" valign="top">
<span class="Bold">% of Patients</span><br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="center" valign="top">
<span class="Bold">Rizatriptan Benzoate Tablets 5 mg<br>            (n = 977)</span><br>
</td>
<td class="Rrule" align="center" valign="top">
<span class="Bold">Rizatriptan Benzoate Tablets 10 mg<br>            (n = 1,167)</span><br>
</td>
<td class="Rrule" align="center" valign="top">
<span class="Bold">Placebo<br>            (n = 627)</span><br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" colspan="2" valign="top">
<span class="Italics">Atypical Sensations</span><br>
</td>
<td class="Rrule" align="center" valign="top">4<br>
</td>
<td class="Rrule" align="center" valign="top">5<br>
</td>
<td class="Rrule" align="center" valign="top">4<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" colspan="2" valign="top"><span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">Paresthesia</span><br>
</td>
<td class="Rrule" align="center" valign="top">3<br>
</td>
<td class="Rrule" align="center" valign="top">4<br>
</td>
<td class="Rrule" align="center" valign="top">&lt; 2<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" colspan="2" valign="top">
<span class="Italics"><span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">Pain</span> and other Pressure Sensations</span><br>
</td>
<td class="Rrule" align="center" valign="top">6<br>
</td>
<td class="Rrule" align="center" valign="top">9<br>
</td>
<td class="Rrule" align="center" valign="top">3<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" colspan="2" valign="top"><span class="product-label-link" type="condition" conceptid="77670" conceptname="Chest pain">Chest Pain</span>:<br>
</td>
<td class="Rrule" align="center" valign="top"> <br>
</td>
<td class="Rrule" align="center" valign="top"> <br>
</td>
<td class="Rrule" align="center" valign="top"> <br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" colspan="2" valign="top">tightness/pressure and/or heaviness<br>
</td>
<td class="Rrule" align="center" valign="top">&lt; 2<br>
</td>
<td class="Rrule" align="center" valign="top">3<br>
</td>
<td class="Rrule" align="center" valign="top">1<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" colspan="2" valign="top">Neck/throat/jaw:<br>
</td>
<td class="Rrule" align="center" valign="top"> <br>
</td>
<td class="Rrule" align="center" valign="top"> <br>
</td>
<td class="Rrule" align="center" valign="top"> <br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" colspan="2" valign="top"><span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>/tightness/pressure<br>
</td>
<td class="Rrule" align="center" valign="top">&lt; 2<br>
</td>
<td class="Rrule" align="center" valign="top">2<br>
</td>
<td class="Rrule" align="center" valign="top">1<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" colspan="2" valign="top">Regional <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">Pain</span>:<br>
</td>
<td class="Rrule" align="center" valign="top"> <br>
</td>
<td class="Rrule" align="center" valign="top"> <br>
</td>
<td class="Rrule" align="center" valign="top"> <br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" colspan="2" valign="top">tightness/pressure and/or heaviness<br>
</td>
<td class="Rrule" align="center" valign="top">&lt; 1<br>
</td>
<td class="Rrule" align="center" valign="top">2<br>
</td>
<td class="Rrule" align="center" valign="top">0<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" colspan="2" valign="top"><span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">Pain</span>, location unspecified<br>
</td>
<td class="Rrule" align="center" valign="top">3<br>
</td>
<td class="Rrule" align="center" valign="top">3<br>
</td>
<td class="Rrule" align="center" valign="top">&lt; 2<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" colspan="2" valign="top">
<span class="Italics">Digestive</span><br>
</td>
<td class="Rrule" align="center" valign="top">9<br>
</td>
<td class="Rrule" align="center" valign="top">13<br>
</td>
<td class="Rrule" align="center" valign="top">8<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" colspan="2" valign="top"><span class="product-label-link" type="condition" conceptid="4226991" conceptname="Aptyalism">Dry Mouth</span><br>
</td>
<td class="Rrule" align="center" valign="top">3<br>
</td>
<td class="Rrule" align="center" valign="top">3<br>
</td>
<td class="Rrule" align="center" valign="top">1<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" colspan="2" valign="top"><span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span><br>
</td>
<td class="Rrule" align="center" valign="top">4<br>
</td>
<td class="Rrule" align="center" valign="top">6<br>
</td>
<td class="Rrule" align="center" valign="top">4<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" colspan="2" valign="top">
<span class="Italics">Neurological</span><br>
</td>
<td class="Rrule" align="center" valign="top">14<br>
</td>
<td class="Rrule" align="center" valign="top">20<br>
</td>
<td class="Rrule" align="center" valign="top">11<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" colspan="2" valign="top"><span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">Dizziness</span><br>
</td>
<td class="Rrule" align="center" valign="top">4<br>
</td>
<td class="Rrule" align="center" valign="top">9<br>
</td>
<td class="Rrule" align="center" valign="top">5<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" colspan="2" valign="top"><span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headache</span><br>
</td>
<td class="Rrule" align="center" valign="top">&lt; 2<br>
</td>
<td class="Rrule" align="center" valign="top">2<br>
</td>
<td class="Rrule" align="center" valign="top">&lt; 1<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" colspan="2" valign="top"><span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">Somnolence</span><br>
</td>
<td class="Rrule" align="center" valign="top">4<br>
</td>
<td class="Rrule" align="center" valign="top">8<br>
</td>
<td class="Rrule" align="center" valign="top">4<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" colspan="2" valign="top">
<span class="Italics">Other</span><br>
</td>
<td class="Rrule" align="center" valign="top"> <br>
</td>
<td class="Rrule" align="center" valign="top"> <br>
</td>
<td class="Rrule" align="center" valign="top"> <br>
</td>
</tr>
<tr class="Botrule Last">
<td class="Lrule Rrule" colspan="2" valign="top"><span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">Asthenia</span>/<span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span><br>
</td>
<td class="Rrule" align="center" valign="top">4<br>
</td>
<td class="Rrule" align="center" valign="top">7<br>
</td>
<td class="Rrule" align="center" valign="top">2<br>
</td>
</tr>
</tbody></table>
<br><p>The frequencies of adverse reactions in clinical trials did not increase when up to three doses were taken within 24 hours. Adverse reaction frequencies were also unchanged by concomitant use of drugs commonly taken for <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraine</span> prophylaxis (including propranolol), oral contraceptives, or analgesics. The incidences of adverse reactions were not affected by age or gender. There were insufficient data to assess the impact of race on the incidence of adverse reactions.</p>
<p><span class="Italics">Other Events Observed in Association with the Administration of Rizatriptan Benzoate in Adults:</span> In the following section, the frequencies of less commonly reported adverse events are presented that were not reported in other sections of the labeling. Because the reports include events observed in open studies, the role of rizatriptan benzoate in their causation cannot be reliably determined. Furthermore, variability associated with adverse event reporting, the terminology used to describe adverse events, limit the value of the quantitative frequency estimates provided. Event frequencies are calculated as the number of patients who used rizatriptan benzoate and reported an event divided by the total number of patients exposed to rizatriptan benzoate (n = 3,716). All reported events occurred at an incidence ≥ 1%, or are believed to be reasonably associated with the use of the drug. Events are further classified within body system categories and enumerated in order of decreasing frequency using the following definitions: frequent adverse events are those defined as those occurring in at least (&gt;) 1/100 patients; infrequent adverse experiences are those occurring in 1/100 to 1/1,000 patients; and rare adverse experiences are those occurring in fewer than 1/1,000 patients.</p>
<p><span class="Underline">General</span>: Infrequent was facial <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span>. Rare were <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">syncope</span> and <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span>/<span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span>.</p>
<p><span class="Underline">Atypical Sensations</span>: Frequent were warm sensations.</p>
<p><span class="Underline">Cardiovascular</span>: Frequent was <span class="product-label-link" type="condition" conceptid="315078" conceptname="Palpitations">palpitation</span>. Infrequent were <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">tachycardia</span>, <span class="product-label-link" type="condition" conceptid="4035643" conceptname="Cold extremities">cold extremities</span>, and <span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">bradycardia</span>.</p>
<p><span class="Underline">Digestive</span>: Frequent were <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>. Infrequent were <span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">dyspepsia</span>, <span class="product-label-link" type="condition" conceptid="4217627" conceptname="Edema of the tongue">tongue edema</span> and abdominal <span class="product-label-link" type="condition" conceptid="4218984" conceptname="Abdominal distension">distention</span>.</p>
<p><span class="Underline">Musculoskeletal</span>: Infrequent were <span class="product-label-link" type="condition" conceptid="79908" conceptname="Muscle weakness">muscle weakness</span>, <span class="product-label-link" type="condition" conceptid="4060220" conceptname="Stiff neck">stiffness</span>, <span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">myalgia</span> and <span class="product-label-link" type="condition" conceptid="75635" conceptname="Cramp">muscle cramp</span>/spasm.</p>
<p><span class="Underline">Neurological/Psychiatric</span>: Frequent were <span class="product-label-link" type="condition" conceptid="4151171" conceptname="Numbness of limbs">hypoesthesia</span>, <span class="product-label-link" type="condition" conceptid="4142453" conceptname="Feeling high">euphoria</span> and <span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">tremor</span>. Infrequent were <span class="product-label-link" type="condition" conceptid="439383" conceptname="Vertigo">vertigo</span>, <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">insomnia</span>, <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">confusion</span>/<span class="product-label-link" type="condition" conceptid="4011527" conceptname="Spatial disorientation">disorientation</span>, gait abnormality, <span class="product-label-link" type="condition" conceptid="4304008" conceptname="Memory impairment">memory impairment</span>, and <span class="product-label-link" type="condition" conceptid="436087" conceptname="Excitement">agitation</span>.</p>
<p><span class="Underline">Respiratory</span>: Frequent was <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">dyspnea</span>. Infrequent was <span class="product-label-link" type="condition" conceptid="4056883" conceptname="Edema of pharynx">pharyngeal edema</span>.</p>
<p><span class="Underline">Special Senses</span>: Infrequent were <span class="product-label-link" type="condition" conceptid="4079185" conceptname="Hazy vision">blurred vision</span> and <span class="product-label-link" type="condition" conceptid="377575" conceptname="Tinnitus">tinnitus</span>. Rare was <span class="product-label-link" type="condition" conceptid="381299" conceptname="Swelling of structure of eye">eye swelling</span>.</p>
<p><span class="Underline">Skin and Skin Appendage</span>: Frequent was <span class="product-label-link" type="condition" conceptid="318566" conceptname="Flushing">flushing</span>. Infrequent were <span class="product-label-link" type="condition" conceptid="138565" conceptname="Hyperhidrosis">sweating</span>, <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span>, <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>, and <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span>. Rare was <span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">erythema</span>, <span class="product-label-link" type="condition" conceptid="4113666" conceptname="Menopausal flushing">hot flashes</span>.</p>
<p>The adverse reaction profile seen with rizatriptan benzoate orally disintegrating tablets was similar to that seen with rizatriptan benzoate tablets.</p>
<p><span class="Italics"><span class="Bold">Pediatric Patients 6 to 17 Years of Age:</span></span><span class="Italics">Information relating to adverse reactions to rizatriptan benzoate orally disintegrating  tablets in a controlled clinical is approved for Merck &amp; Co., Inc.'s Rizatriptan Benzoate Orally Disintegrating Tablets in pediatric patients (6 to 17 years old). However, due to Merck &amp; Co., Inc.'s marketing exclusivity rights, this drug product is not labeled with that information.</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_6.2"></a><a name="section-6.2"></a><p></p>
<h2>6.2 Post-marketing Experience</h2>
<p class="First">The following section enumerates potentially important adverse events that have occurred in clinical practice and which have been reported spontaneously to various surveillance systems. The events enumerated include all except those already listed in other sections of the labeling or those too general to be informative. Because the reports cite events reported spontaneously from worldwide post-marketing experience, frequency of events and the role of rizatriptan benzoate in their causation cannot be reliably determined.</p>
<p><span class="Italics"><span class="Bold">Neurological/Psychiatric:</span></span> <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">Seizure</span>.</p>
<p><span class="Italics"><span class="Bold">General</span></span>: Allergic conditions including <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylaxis</span>/<span class="product-label-link" type="condition" conceptid="4148381" conceptname="Anaphylactoid reaction">anaphylactoid reaction</span>, <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">angioedema</span>, <span class="product-label-link" type="condition" conceptid="314754" conceptname="Wheezing">wheezing</span>, and <span class="product-label-link" type="condition" conceptid="443754" conceptname="Lyell's toxic epidermal necrolysis, subepidermal type">toxic epidermal necrolysis</span> <span class="Italics">[see Contraindications (<a href="#Section_4">4</a>)]</span>.</p>
<p><span class="Italics"><span class="Bold">Special Senses:</span></span> <span class="product-label-link" type="condition" conceptid="436235" conceptname="Taste sense altered">Dysgeusia</span>.</p>
</div>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="Section_7"></a><a name="section-7"></a><p></p>
<h1>7 DRUG INTERACTIONS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_7.1"></a><a name="section-7.1"></a><p></p>
<h2>7.1 Propranolol</h2>
<p class="First">The dose of rizatriptan benzoate should be adjusted in propranolol-treated patients, as propranolol has been shown to increase the plasma AUC of rizatriptan by 70% <span class="Italics">[see Dosage and Administration (<a href="#Section_2.5">2.4</a>) and Clinical Pharmacology (<a href="#Section_12.3">12.3</a>)].</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_7.2"></a><a name="section-7.2"></a><p></p>
<h2>7.2 Ergot-containing Drugs</h2>
<p class="First">Ergot-containing drugs have been reported to cause prolonged vasospastic reactions. Because these effects may be additive, use of ergotamine-containing or ergot-type medications (like dihydroergotamine or methysergide) and rizatriptan benzoate within 24 hours is contraindicated <span class="Italics">[see Contraindications (<a href="#Section_4">4</a>)].</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_7.3"></a><a name="section-7.3"></a><p></p>
<h2>7.3 Other 5-HT1 Agonists</h2>
<p class="First">Because their vasospastic effects may be additive, coadministration of rizatriptan benzoate and other 5-HT<span class="Sub">1</span> agonists within 24 hours of each other is contraindicated <span class="Italics">[see Contraindications (<a href="#Section_4">4</a>)]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_7.4"></a><a name="section-7.4"></a><p></p>
<h2>7.4 SSRIs/SNRIs and <span class="product-label-link" type="condition" conceptid="4154707" conceptname="Serotonin syndrome">Serotonin Syndrome</span></h2>
<p class="First">Cases of <span class="product-label-link" type="condition" conceptid="4154707" conceptname="Serotonin syndrome">serotonin syndrome</span> have been reported during coadministration of triptans and selective serotonin reuptake inhibitors (SSRIs) or serotonin norepinephrine reuptake inhibitors (SNRIs) <span class="Italics">[see Warnings and Precautions (<a href="#Section_5.7">5.7</a>)].</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_7.5"></a><a name="section-7.5"></a><p></p>
<h2>7.5 Monoamine Oxidase Inhibitors</h2>
<br><p class="First">Rizatriptan benzoate is contraindicated in patients taking MAO-A inhibitors and non-selective MAO inhibitors. A specific MAO-A inhibitor increased the systemic exposure of rizatriptan and its metabolite <span class="Italics">[see Contraindications (<a href="#Section_4">4</a>) and Clinical Pharmacology (<a href="#Section_12.3">12.3</a>)].</span></p>
</div>
</div>
<div class="Section" data-sectionCode="43684-0">
<a name="Section_8"></a><a name="section-8"></a><p></p>
<h1>8 USE IN SPECIFIC POPULATIONS</h1>
<div class="Section" data-sectionCode="42228-7">
<a name="Section_8.1"></a><a name="section-8.1"></a><p></p>
<h2>8.1 Pregnancy</h2>
<p class="First"><span class="Italics">Pregnancy Category C</span>: There are no adequate and well controlled studies in pregnant women. Rizatriptan benzoate should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.</p>
<p>In a general reproductive study in rats, birth weights and pre- and post-weaning <span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">weight gain</span> were reduced in the offspring of females treated prior to and during mating and throughout gestation and lactation with doses of 10 and 100 mg/kg/day. In a pre- and postnatal developmental toxicity study in rats, an increase in mortality of the offspring at birth and for the first 3 days after birth, a decrease in pre- and post-weaning <span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">weight gain</span>, and decreased performance in a passive avoidance test (which indicates a decrease in learning capacity of the offspring) were observed at doses of 100 and 250 mg/kg/day. The no-effect dose for all of these effects was 5 mg/kg/day, associated with a maternal plasma exposure (AUC) approximately 7.5 times that in humans receiving the MRDD. With doses of 100 and 250 mg/kg/day, the decreases in average weight of both the male and female offspring persisted into adulthood. All effects on the offspring in both studies occurred in the absence of any apparent maternal toxicity.</p>
<p>In embryofetal development studies, no teratogenic effects were observed when pregnant rats and rabbits were administered doses of 100 and 50 mg/kg/day, respectively, during organogenesis. Fetal weights were decreased in conjunction with decreased maternal <span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">weight gain</span> at the highest doses tested. The developmental no-effect dose in these studies was 10 mg/kg/day in both rats and rabbits (maternal exposures approximately 15 times human exposure at the MRDD). Toxicokinetic studies demonstrated placental transfer of drug in both species.</p>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="Section_8.3"></a><a name="section-8.2"></a><p></p>
<h2>8.3 Nursing Mothers</h2>
<p class="First">It is not known whether this drug is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when rizatriptan benzoate is administered to a nursing woman. Rizatriptan is extensively excreted in rat milk, with levels in milk at least 5-fold higher than levels in maternal plasma.</p>
<br>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="Section_8.4"></a><a name="section-8.3"></a><p></p>
<h2>8.4 Pediatric Use</h2>
<p class="First">Safety and effectiveness in pediatric patients under 6 years of age have not been established.</p>
<p><span class="Italics">Information related to the efficacy and safety of rizatriptan benzoate in the acute treatment of <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraine</span> in patients aged 6 to 17 years is approved for Merck &amp; Co., Inc.'s Rizatriptan Benzoate Orally Disintegrating Tablets. However, due to Merck &amp; Co., Inc.'s marketing exclusivity rights, this drug product is not labeled with that information</span><span class="Italics">[see Clinical Studies (<a href="#Section_14.2">14.2</a>)].</span></p>
</div>
<div class="Section" data-sectionCode="34082-8">
<a name="Section_8.5"></a><a name="section-8.4"></a><p></p>
<h2>8.5 Geriatric Use</h2>
<p class="First">Clinical studies of rizatriptan benzoate did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. Other reported clinical experience has not identified differences in responses between the elderly and younger patients.</p>
<p>Although the pharmacokinetics of rizatriptan were similar in elderly (aged ≥ 65 years) and in younger adults (n = 17), in general, dose selection for an elderly patient should be cautious, starting at the low end of the dosing range. This reflects the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy.</p>
<p>Geriatric patients who have other cardiovascular risk factors (e.g., <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span>, <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>, smoking, <span class="product-label-link" type="condition" conceptid="433736" conceptname="Obesity">obesity</span>, strong family history of <span class="product-label-link" type="condition" conceptid="317576" conceptname="Coronary arteriosclerosis">coronary artery disease</span>) should have a cardiovascular evaluation prior to receiving rizatriptan benzoate <span class="Italics">[see Warnings and Precautions (<a href="#Section_5.1">5.1</a>)].<br></span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_8.6"></a><a name="section-8.5"></a><p></p>
<h2>8.6 Patients with <span class="product-label-link" type="condition" conceptid="432872" conceptname="Phenylketonuria">Phenylketonuria</span></h2>
<br><p class="First">Rizatriptan benzoate orally disintegrating tablets contain phenylalanine (a component of aspartame). The 5 mg and 10 mg orally disintegrating tablets contain 0.84 mg and 1.68 mg phenylalanine, respectively.</p>
</div>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="Section_10"></a><a name="section-9"></a><p></p>
<h1>10 OVERDOSAGE</h1>
<p class="First">No <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdoses</span> of rizatriptan benzoate were reported during clinical trials in adults.</p>
<p>Some adult patients who received 40 mg of rizatriptan benzoate either a single dose or as two doses with a 2-hour interdose interval had <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span> and <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">somnolence</span>.</p>
<p>In a clinical pharmacology study in which 12 adult subjects received rizatriptan benzoate, at total cumulative doses of 80 mg (given within 4 hours), two of the subjects experienced <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">syncope</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, <span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">bradycardia</span> including <span class="product-label-link" type="condition" conceptid="320744" conceptname="Complete atrioventricular block">third degree AV block</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, and/or <span class="product-label-link" type="condition" conceptid="444035" conceptname="Incontinence">incontinence</span>.</p>
<p>In addition, based on the pharmacology of rizatriptan benzoate, <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span> or <span class="product-label-link" type="condition" conceptid="4124683" conceptname="Silent myocardial ischemia">myocardial ischemia</span> could occur after overdosage. Gastrointestinal decontamination, (i.e., gastric lavage followed by activated charcoal) should be considered in patients suspected of an <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> with rizatriptan benzoate. Clinical and electrocardiographic monitoring should be continued for at least 12 hours, even if clinical symptoms are not observed.</p>
<p>The effects of hemo- or peritoneal dialysis on serum concentrations of rizatriptan are unknown.</p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="Section_11"></a><a name="section-10"></a><p></p>
<h1>11 DESCRIPTION</h1>
<p class="First">Rizatriptan benzoate orally disintegrating tablets contain rizatriptan benzoate, a selective 5-hydroxytryptamine<span class="Sub">1B/1D</span> (5-HT<span class="Sub">1B/1D </span>) receptor agonist.</p>
<p>Rizatriptan benzoate is described chemically as: <span class="Italics">N,N</span>-dimethyl-5-(1<span class="Italics">H</span>-1,2,4-triazol-1-ylmethyl)-1<span class="Italics">H</span>-indole-3-ethanamine monobenzoate and its structural formula is:<br><br><br><img alt="structure" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=57ed2505-28f1-4292-b3c3-a49bf0f7c683&amp;name=rizatriptan-structure.jpg"><br><br><br><br></p>
<p>Its molecular formula is C<span class="Sub">15</span>H<span class="Sub">19</span>N<span class="Sub">5</span>•C<span class="Sub">7</span>H<span class="Sub">6</span>O<span class="Sub">2</span>, representing a molecular weight of the free base of 269.4. Rizatriptan benzoate, USP is a white to off-white, crystalline solid that is soluble in water at about 42 mg per mL (expressed as free base) at 25°C.</p>
<p>Rizatriptan benzoate orally disintegrating tablets are available for oral administration in strengths of 5 mg and 10 mg (corresponding to 7.265 mg or 14.53 mg of the benzoate salt, respectively). <br>Each orally disintegrating tablet contains following inactive ingredients:<br>microcrystalline cellulose, colloidal silicon dioxide, carboxymethyl cellulose calcium, magnesium stearate, mannitol, aspartame, and peppermint flavor.</p>
<br>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="Section_12"></a><a name="section-11"></a><p></p>
<h1>12 CLINICAL PHARMACOLOGY</h1>
<div class="Section" data-sectionCode="43679-0">
<a name="Section_12.1"></a><a name="section-11.1"></a><p></p>
<h2>12.1 Mechanism of Action</h2>
<p class="First">Rizatriptan binds with high affinity to human cloned 5-HT<span class="Sub">1B/1D</span> receptors. Rizatriptan presumably exerts its therapeutic effects in the treatment of <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraine headache</span> by binding to 5-HT<span class="Sub">1B/1D</span> receptors located on intracranial blood vessels and sensory nerves of the trigeminal system.</p>
</div>
<div class="Section" data-sectionCode="43682-4">
<a name="Section_12.3"></a><a name="section-11.2"></a><p></p>
<h2>12.3 Pharmacokinetics</h2>
<p class="First"><span class="Bold"><span class="Italics">Absorption</span></span>: Rizatriptan is completely absorbed following oral administration. The mean oral absolute bioavailability of the rizatriptan benzoate tablet is about 45%, and mean peak plasma concentrations (C<span class="Sub">max</span>) are reached in approximately 1 to 1.5 hours (T<span class="Sub">max</span>). The presence of a <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraine headache</span> did not appear to affect the absorption or pharmacokinetics of rizatriptan. Food has no significant effect on the bioavailability of rizatriptan but delays the time to reach peak concentration by an hour. In clinical trials, rizatriptan benzoate was administered without regard to food.</p>
<p>The bioavailability and C<span class="Sub">max</span> of rizatriptan were similar following administration of rizatriptan benzoate orally disintegrating tablets, but the rate of absorption is somewhat slower with rizatriptan benzoate orally disintegrating tablets, with T<span class="Sub">max</span> delayed by up to 0.7 hour. AUC of rizatriptan is approximately 30% higher in females than in males. No accumulation occurred on multiple dosing.</p>
<p><span class="Bold"><span class="Italics">Distribution</span></span>: The mean volume of distribution is approximately 140 liters in male subjects and 110 liters in female subjects. Rizatriptan is minimally bound (14%) to plasma proteins.</p>
<p><span class="Bold"><span class="Italics">Metabolism</span></span>: The primary route of rizatriptan metabolism is via oxidative deamination by monoamine oxidase-A (MAO-A) to the indole acetic acid metabolite, which is not active at the 5-HT<span class="Sub">1B/1D</span> receptor. N-monodesmethyl-rizatriptan, a metabolite with activity similar to that of parent compound at the 5-HT<span class="Sub">1B/1D</span> receptor, is formed to a minor degree. Plasma concentrations of N-monodesmethyl-rizatriptan are approximately 14% of those of parent compound, and it is eliminated at a similar rate. Other minor metabolites, the N-oxide, the 6-hydroxy compound, and the sulfate conjugate of the 6-hydroxy metabolite are not active at the 5-HT<span class="Sub">1B/1D</span> receptor.</p>
<p><span class="Bold"><span class="Italics">Elimination</span></span>: The total radioactivity of the administered dose recovered over 120 hours in urine and feces was 82% and 12%, respectively, following a single 10 mg oral administration of <span class="Sup">14</span>C-rizatriptan. Following oral administration of <span class="Sup">14</span>C-rizatriptan, rizatriptan accounted for about 17% of circulating plasma radioactivity. Approximately 14% of an oral dose is excreted in urine as unchanged rizatriptan while 51% is excreted as indole acetic acid metabolite, indicating substantial first-pass metabolism.</p>
<p>The plasma half-life of rizatriptan in males and females averages 2 to 3 hours. </p>
<p><span class="Bold"><span class="Italics">Cytochrome P450 Isoforms</span></span>: Rizatriptan is not an inhibitor of the activities of human liver cytochrome P450 isoforms 3A4/5, 1A2, 2C9, 2C19, or 2E1; rizatriptan is a competitive inhibitor (Ki = 1400 nM) of cytochrome P450 2D6, but only at high, clinically irrelevant concentrations. </p>
<p><span class="Bold"><span class="Italics">Special Populations</span></span>: <span class="Italics">Geriatric:</span> Rizatriptan pharmacokinetics in healthy elderly non-migraineur volunteers (age 65 to 77 years) were similar to those in younger non-migraineur volunteers (age 18 to 45 years).</p>
<p><span class="Italics">Pediatric: Information related to the pharmacokinetics of rizatriptan in pediatric migraineurs 6 to 17 years of age is approved for Merck &amp; Co., Inc.'s Rizatriptan Benzoate Orally Disintegrating Tablets. However, due to Merck &amp; Co., Inc.'s marketing exclusivity rights, this drug product is not labeled with that information.</span></p>
<p><span class="Italics">Gender</span>: The mean AUC<span class="Sub">0-∞</span> and C<span class="Sub">max</span> of rizatriptan (10 mg orally) were about 30% and 11% higher in females as compared to males, respectively, while T<span class="Sub">max</span> occurred at approximately the same time.</p>
<p><span class="Italics"><span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span></span>: Following oral administration in patients with <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> caused by mild to moderate <span class="product-label-link" type="condition" conceptid="196463" conceptname="Alcoholic cirrhosis">alcoholic cirrhosis</span> of the liver, plasma concentrations of rizatriptan were similar in patients with mild <span class="product-label-link" type="condition" conceptid="4245975" conceptname="Hepatic failure">hepatic insufficiency</span> compared to a control group of subjects with normal hepatic function; plasma concentrations of rizatriptan were approximately 30% greater in patients with moderate <span class="product-label-link" type="condition" conceptid="4245975" conceptname="Hepatic failure">hepatic insufficiency</span>.</p>
<p><span class="Italics"><span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span></span>: In patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> (creatinine clearance 10 to 60 mL/min/1.73 m<span class="Sup">2</span>), the AUC<span class="Sub">0-∞</span> of rizatriptan was not significantly different from that in subjects with normal renal function. In hemodialysis patients, (creatinine clearance &lt; 2 mL/min/1.73 m<span class="Sup">2</span>), however, the AUC for rizatriptan was approximately 44% greater than that in patients with normal renal function.</p>
<p><span class="Italics">Race</span>: Pharmacokinetic data revealed no significant differences between African American and Caucasian subjects. </p>
<p><span class="Bold"><span class="Italics">Drug Interactions</span></span>: <span class="Italics">[See also Drug Interactions (<a href="#Section_7">7</a>).]</span></p>
<p><span class="Italics">Monoamine Oxidase Inhibitors</span>: Rizatriptan is principally metabolized via monoamine oxidase, 'A' subtype (MAO-A). Plasma concentrations of rizatriptan may be increased by drugs that are selective MAO-A inhibitors (e.g., moclobemide) or nonselective MAO inhibitors [type A and B] (e.g., isocarboxazid, phenelzine, tranylcypromine, and pargyline). In a drug interaction study, when rizatriptan 10 mg was administered to subjects (n = 12) receiving concomitant therapy with the selective, reversible MAO-A inhibitor, moclobemide 150 mg t.i.d., there were mean increases in rizatriptan AUC and C<span class="Sub">max</span> of 119% and 41% respectively; and the AUC of the active N-monodesmethyl metabolite of rizatriptan was increased more than 400%. The interaction would be expected to be greater with irreversible MAO inhibitors. No <span class="product-label-link" type="condition" conceptid="4196500" conceptname="Drug interaction">pharmacokinetic interaction</span> is anticipated in patients receiving selective MAO-B inhibitors <span class="Italics">[see Contraindications (<a href="#Section_4">4</a>) and Drug Interactions (<a href="#Section_7.5">7.5</a>)].</span></p>
<p><span class="Italics">Propranolol</span>: In a study of concurrent administration of propranolol 240 mg/day and a single dose of rizatriptan 10 mg in healthy adult subjects (n = 11), mean plasma AUC for rizatriptan was increased by 70% during propranolol administration, and a 4-fold increase was observed in one subject. The AUC of the active N-monodesmethyl metabolite of rizatriptan was not affected by propranolol <span class="Italics">[see Dosage and Administration (<a href="#Section_2.5">2.4</a>) and Drug Interactions (<a href="#Section_7.1">7.1</a>)].</span></p>
<p><span class="Italics">Nadolol/Metoprolol</span>: In a drug interactions study, effects of multiple doses of nadolol 80 mg or metoprolol 100 mg every 12 hours on the pharmacokinetics of a single dose of 10 mg rizatriptan were evaluated in healthy subjects (n = 12). No <span class="product-label-link" type="condition" conceptid="4196500" conceptname="Drug interaction">pharmacokinetic interactions</span> were observed.</p>
<p><span class="Italics">Paroxetine</span>: In a study of the interaction between the selective serotonin reuptake inhibitor (SSRI) paroxetine 20 mg/day for 2 weeks and a single dose of rizatriptan 10 mg in healthy subjects (n = 12), neither the plasma concentrations of rizatriptan nor its safety profile were affected by paroxetine <span class="Italics">[see Warnings and Precautions (<a href="#Section_5.7">5.7</a>), Drug Interactions (<a href="#Section_7.4">7.4</a>), and Patient Counseling Information (<a href="#Section_16">17</a>)].</span></p>
<p><span class="Italics">Oral Contraceptives</span>: In a study of concurrent administration of an oral contraceptive during 6 days of administration of rizatriptan (10 to 30 mg/day) in healthy female volunteers (n = 18), rizatriptan did not affect plasma concentrations of ethinyl estradiol or norethindrone.</p>
<br>
</div>
</div>
<div class="Section" data-sectionCode="43680-8">
<a name="Section_13"></a><a name="section-12"></a><p></p>
<h1>13 NONCLINICAL TOXICOLOGY</h1>
<div class="Section" data-sectionCode="34083-6">
<a name="Section_13.1"></a><a name="section-12.1"></a><p></p>
<h2>13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</h2>
<p class="First"><span class="Bold"><span class="Italics">Carcinogenesis</span></span>: Oral carcinogenicity studies were conducted in mice (100 weeks) and rats (106 weeks) at doses of up to 125 mg/kg/day. Plasma exposures (AUC) at the highest dose tested were approximately 150 (mice) and 240 times (rats) that in humans at the maximum recommended daily dose (MRDD) of 30 mg/day. There was no evidence of an increase in tumor incidence related to rizatriptan in either species.</p>
<p><span class="Bold"><span class="Italics">Mutagenesis</span></span>: Rizatriptan was neither mutagenic nor clastogenic in a battery of <span class="Italics">in vitro</span> and <span class="Italics">in vivo</span> genetic toxicity studies, including: the microbial mutagenesis (Ames) assay, <span class="Italics">in vitro</span> mammalian cell mutagenesis and chromosomal aberration assays, and the <span class="Italics">in vivo</span> chromosomal aberration assay in mouse.</p>
<p><span class="Bold"><span class="Italics">Impairment of Fertility</span></span>: In a fertility study in rats, altered estrus cyclicity and delays in time to mating were observed in females treated orally with 100 mg/kg/day rizatriptan. The no-effect dose was 10 mg/kg/day (approximately 15 times the human exposure at the MRDD). There were no other fertility-related effects in the female rats. There was no impairment of fertility or reproductive performance in male rats treated with up to 250 mg/kg/day (approximately 550 times the human exposure at the MRDD).</p>
</div>
</div>
<div class="Section" data-sectionCode="34092-7">
<a name="Section_14"></a><a name="section-13"></a><p></p>
<h1>14 CLINICAL STUDIES</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_14.1"></a><a name="section-13.1"></a><p></p>
<h2>14.1 Adults</h2>
<p class="First">The efficacy of rizatriptan benzoate tablets was established in four multicenter, randomized, placebo-controlled trials. Patients enrolled in these studies were primarily female (84%) and Caucasian (88%), with a mean age of 40 years (range of 18 to 71). Patients were instructed to treat a moderate to severe <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>. <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headache</span> response, defined as a reduction of moderate or severe <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span> <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> to no or mild <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span> <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>, was assessed for up to 2 hours (Study 1) or up to 4 hours after dosing (Studies 2, 3 and 4). Associated symptoms of <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="4260194" conceptname="Photophobia">photophobia</span>, and <span class="product-label-link" type="condition" conceptid="4209114" conceptname="Phonophobia">phonophobia</span> and maintenance of response up to 24 hours post-dose were evaluated. A second dose of rizatriptan benzoate tablets was allowed 2 to 24 hours after dosing for treatment of recurrent <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span> in Studies 1 and 2. Additional analgesics and/or antiemetics were allowed 2 hours after initial treatment for rescue in all four studies.</p>
<p>In all studies, the percentage of patients achieving <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span> response 2 hours after treatment was significantly greater in patients who received either rizatriptan benzoate 5 mg or 10 mg compared to those who received placebo. In a separate study, doses of 2.5 mg were not different from placebo. Doses greater than 10 mg were associated with an increased incidence of adverse effects. The results from the four controlled studies are summarized in Table 2.</p>
<br><br><p><span class="Bold">Table 2: Response Rates 2 Hours Following Treatment of Initial <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headache</span> in Studies 1, 2, 3, and 4</span></p>
<br><br><table border="0" cellpadding="0" cellspacing="0" width="100%">
<tfoot><tr><td colspan="0" align="left"><dl class="Footnote">
<dt><a name="footnote-1" href="#footnote-reference-1">*</a></dt>
<dd>p-value &lt; 0.05 in comparison with placebo</dd>
<dt><a name="footnote-2" href="#footnote-reference-2">†</a></dt>
<dd>p-value &lt; 0.05 in comparison with 5 mg</dd>
<dt><a name="footnote-3" href="#footnote-reference-3">‡</a></dt>
<dd>Results for initial <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span> only.</dd>
</dl></td></tr></tfoot>
<tbody class="Headless">
<tr class="Botrule First">
<td class="Lrule Rrule" align="center" valign="top">
<span class="Bold">Study</span><br>
</td>
<td class="Rrule" align="center" colspan="2" valign="top">
<span class="Bold">Placebo</span><br>
</td>
<td class="Rrule" align="center" colspan="2" valign="top"><span class="Bold">Rizatriptan Benzoate Tablets <br>            5 mg<br></span></td>
<td class="Rrule" align="center" colspan="2" valign="top"><span class="Bold">Rizatriptan Benzoate Tablets<br>            10 mg<br></span></td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="center" valign="top">1<br>
</td>
<td class="Rrule" align="center" valign="top">35%<br>
</td>
<td class="Rrule" align="center" valign="top">(n = 304)<br>
</td>
<td class="Rrule" align="center" valign="top">62%<a name="footnote-reference-1" href="#footnote-1" class="Sup">*</a><br>
</td>
<td class="Rrule" align="center" valign="top">(n = 458)<br>
</td>
<td class="Rrule" align="center" valign="top">71%<a href="#footnote-1" class="Sup">*</a><span class="Sup">,</span><a name="footnote-reference-2" href="#footnote-2" class="Sup">†</a><br>
</td>
<td class="Rrule" align="center" valign="top">(n = 456)<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="center" valign="top">2<a name="footnote-reference-3" href="#footnote-3" class="Sup">‡</a><br>
</td>
<td class="Rrule" align="center" valign="top">37%<br>
</td>
<td class="Rrule" align="center" valign="top">(n = 82)<br>
</td>
<td class="Rrule" align="center" valign="top">  <br>
</td>
<td class="Rrule" align="center" valign="top">—<br>
</td>
<td class="Rrule" align="center" valign="top">77%<a href="#footnote-1" class="Sup">*</a><br>
</td>
<td class="Rrule" align="center" valign="top">(n = 320)<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="center" valign="top">3<br>
</td>
<td class="Rrule" align="center" valign="top">23%<br>
</td>
<td class="Rrule" align="center" valign="top">(n = 80)<br>
</td>
<td class="Rrule" align="center" valign="top">63%<a href="#footnote-1" class="Sup">*</a><br>
</td>
<td class="Rrule" align="center" valign="top">(n = 352)<br>
</td>
<td class="Rrule" align="center" valign="top">  <br>
</td>
<td class="Rrule" align="center" valign="top">—<br>
</td>
</tr>
<tr class="Last">
<td class="Lrule Rrule" align="center" valign="top">4<br>
</td>
<td class="Rrule" align="center" valign="top">40%<br>
</td>
<td class="Rrule" align="center" valign="top">(n = 159)<br>
</td>
<td class="Rrule" align="center" valign="top">60%<a href="#footnote-1" class="Sup">*</a><br>
</td>
<td class="Rrule" align="center" valign="top">(n = 164)<br>
</td>
<td class="Rrule" align="center" valign="top">67%<a href="#footnote-1" class="Sup">*</a><br>
</td>
<td class="Rrule" align="center" valign="top">(n = 385)<br>
</td>
</tr>
</tbody>
</table>
<br><br><br><p>Comparisons of drug performance based upon results obtained in different clinical trials may not be reliable. Because studies are conducted at different times, with different samples of patients, by different investigators, employing different criteria and/or different interpretations of the same criteria, under different conditions (dose, dosing regimen, etc.), quantitative estimates of treatment response and the timing of response may be expected to vary considerably from study to study.</p>
<p>The estimated probability of achieving an initial <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span> response within 2 hours following treatment in pooled Studies 1, 2, 3, and 4 is depicted in Figure 1.</p>
<p><span class="Bold">Figure 1: Estimated Probability of Achieving an Initial <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headache</span> Response by 2 Hours in Pooled Studies 1, 2, 3, and 4<span class="Sup">††</span><br></span></p>
<br><div class="Figure"><img alt="figure-1" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=57ed2505-28f1-4292-b3c3-a49bf0f7c683&amp;name=rizatriptan-figure-1.jpg"></div>
<br><br><br><p><span class="Sup">††</span> Figure 1 shows the Kaplan-Meier plot of the probability over time of obtaining <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span> response (no or mild <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>) following treatment with rizatriptan benzoate or placebo. The averages displayed are based on pooled data from four placebo-controlled, outpatient trials providing evidence of efficacy (Studies 1, 2, 3, and 4). Patients taking additional treatment or not achieving <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span> response prior to 2 hours were censored at 2 hours.</p>
<p>For patients with <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraine</span>-associated <span class="product-label-link" type="condition" conceptid="4260194" conceptname="Photophobia">photophobia</span>, <span class="product-label-link" type="condition" conceptid="4209114" conceptname="Phonophobia">phonophobia</span>, and <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> at baseline, there was a decreased incidence of these symptoms following administration of rizatriptan benzoate compared to placebo.</p>
<p>Two to 24 hours following the initial dose of study treatment, patients were allowed to use additional treatment for <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> response in the form of a second dose of study treatment or other medication. The estimated probability of patients taking a second dose or other medication for <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraine</span> over the 24 hours following the initial dose of study treatment is summarized in Figure 2.</p>
<p><span class="Bold">Figure 2: Estimated Probability of Patients Taking a Second Dose of Rizatriptan Benzoate Tablets or Other Medication for <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">Migraines</span> Over the 24 Hours Following the Initial Dose of Study Treatment in Pooled Studies 1, 2, 3, and 4<span class="Sup">†††</span></span></p>
<br><br><div class="Figure"><img alt="figure-2" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=57ed2505-28f1-4292-b3c3-a49bf0f7c683&amp;name=rizatriptan-figure-2.jpg"></div>
<br><br><p><span class="Sup">†††</span> This Kaplan-Meier plot is based on data obtained in four placebo-controlled outpatient clinical trials (Studies 1, 2, 3, and 4). Patients not using additional treatments were censored at 24 hours. The plot includes both patients who had <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span> response at 2 hours and those who had no response to the initial dose. Remedication was not allowed within 2 hours post-dose.</p>
<p>Efficacy was unaffected by the presence of <span class="product-label-link" type="condition" conceptid="4091160" conceptname="Aura">aura</span>; by the gender, or age of the patient; or by concomitant use of common <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraine</span> <span class="product-label-link" type="condition" conceptid="4118659" conceptname="Prophylactic">prophylactic</span> drugs (e.g., beta-blockers, calcium channel blockers, tricyclic antidepressants) or oral contraceptives. In two additional similar studies, efficacy was unaffected by relationship to menses. There were insufficient data to assess the impact of race on efficacy. </p>
<p><span class="Bold">Rizatriptan Benzoate Orally Disintegrating Tablets</span></p>
<p>The efficacy of rizatriptan benzoate orally disintegrating tablets was established in two multicenter, randomized, placebo-controlled trials that were similar in design to the trials of rizatriptan benzoate tablets (Studies 5 and 6). Patients were instructed to treat a moderate to severe <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>. Patients treated in these studies were primarily female (88%) and Caucasian (95%), with a mean age of 42 years (range 18 to 72).<br> <br>In both studies, the percentage of patients achieving <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span> response 2 hours after treatment was significantly greater in patients who received either rizatriptan benzoate orally disintegrating tablets 5 or 10 mg compared to those who received placebo. The results from Studies 5 and 6 are summarized in Table 3. </p>
<br><p><span class="Bold">Table 3: Response Rates 2 Hours Following Treatment of Initial <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headache</span> in Studies 5 and 6</span></p>
<br><br><table border="0" cellpadding="0" cellspacing="0" width="100%">
<tfoot><tr><td colspan="0" align="left"><dl class="Footnote">
<dt><a name="footnote-4" href="#footnote-reference-4">*</a></dt>
<dd>p-value &lt;0.01 in comparison with placebo</dd>
<dt><a name="footnote-5" href="#footnote-reference-5">†</a></dt>
<dd>p-value &lt;0.01 in comparison with 5 mg</dd>
</dl></td></tr></tfoot>
<tbody class="Headless">
<tr class="Botrule First">
<td class="Lrule Rrule" align="center" valign="top">Study<br>
</td>
<td class="Rrule" align="center" valign="top">Placebo<br>
</td>
<td class="Rrule" align="center" valign="top">Rizatriptan Benzoate Orally Disintegrating Tablets<br>            5 mg<br>
</td>
<td class="Rrule" align="center" valign="top">Rizatriptan Benzoate Orally Disintegrating Tablets <br>10 mg<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="center" valign="top">5<br>
</td>
<td class="Rrule" align="center" valign="top">47% (n=98)<br>
</td>
<td class="Rrule" align="center" valign="top">66%<a name="footnote-reference-4" href="#footnote-4" class="Sup">*</a> (n=100)<br>
</td>
<td class="Rrule" align="center" valign="top">66%<a href="#footnote-4" class="Sup">*</a> (n=113)<br>
</td>
</tr>
<tr class="Last">
<td class="Lrule Rrule" align="center" valign="top">6<br>
</td>
<td class="Rrule" align="center" valign="top">28% (n=180)<br>
</td>
<td class="Rrule" align="center" valign="top">59%<a href="#footnote-4" class="Sup">*</a>(n=181)<br>
</td>
<td class="Rrule" align="center" valign="top">74%<a href="#footnote-4" class="Sup">*</a><span class="Sup">,</span><a name="footnote-reference-5" href="#footnote-5" class="Sup">†</a> (n=186)<br>
</td>
</tr>
</tbody>
</table>
<br><p>The estimated probability of achieving an initial <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span> response by 2 hours following treatment with rizatriptan benzoate orally disintegrating tablets in pooled Studies 5 and 6 is depicted in Figure 3.</p>
<p><span class="Bold">Figure 3: Estimated Probability of Achieving an Initial <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headache</span> Response with Rizatriptan Benzoate Orally Disintegrating Tablets by 2 Hours in Pooled Studies 5 and 6<span class="Sup">‡</span><br><br><img alt="figure-3" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=57ed2505-28f1-4292-b3c3-a49bf0f7c683&amp;name=rizatriptan-figure-3.jpg"><br><br></span></p>
<p><span class="Sup">‡</span> Figure 3 shows the Kaplan-Meier plot of the probability over time of obtaining <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span> response (no or mild <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>) following treatment with rizatriptan benzoate orally disintegrating tablets or placebo. The averages displayed are based on pooled data from 2 placebo-controlled, outpatient trials providing evidence of efficacy (Studies 5 and 6). Patients taking additional treatment or not achieving <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span> response prior to 2 hours were censored at 2 hours.</p>
<p>For patients with <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraine</span>-associated <span class="product-label-link" type="condition" conceptid="4260194" conceptname="Photophobia">photophobia</span> and <span class="product-label-link" type="condition" conceptid="4209114" conceptname="Phonophobia">phonophobia</span> at baseline, there was a decreased incidence of these symptoms following administration of rizatriptan benzoate orally disintegrating tablets as compared to placebo.</p>
<p>Two to 24 hours following the initial dose of study treatment, patients were allowed to use additional treatment for <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> response in the form of a second dose of study treatment or other medication. The estimated probability of patients taking a second dose or other medication for <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraine</span> over the 24 hours following the initial dose of study treatment is summarized in Figure 4.</p>
<p><span class="Bold">Figure 4: Estimated Probability of Patients Taking a Second Dose of Rizatriptan Benzoate Orally Disintegrating Tablets or Other Medication for <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">Migraines</span> Over the 24 Hours Following the Initial Dose of Study Treatment in Pooled Studies 5 and 6<span class="Sup">‡‡</span><br><br><img alt="figure-4" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=57ed2505-28f1-4292-b3c3-a49bf0f7c683&amp;name=rizatriptan-figure-4.jpg"><br><br></span></p>
<p><span class="Sup">‡‡</span>This Kaplan-Meier plot is based on data obtained in 2 placebo-controlled outpatient clinical trials (Studies 5 and 6). Patients not using additional treatments were censored at 24 hours. The plot includes both patients who had <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span> response at 2 hours and those who had no response to the initial dose. Remedication was not allowed within 2 hours post-dose.</p>
<br><br><br><br>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_14.2"></a><a name="section-13.2"></a><p></p>
<h2>14.2 Pediatric Patients 6 to 17 Years of Age</h2>
<p class="First"><span class="Italics">Information contained in a clinical study relating to the efficacy of rizatriptan benzoate orally disintegrating tablets in pediatric patients (6 to 17 years old) is approved for Merck &amp; Co., Inc.'s Rizatriptan Benzoate Tablets. However, due to Merck &amp; Co., Inc.'s marketing exclusivity rights, this drug product is not labeled with that information.<br></span></p>
</div>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="Section_17"></a><a name="section-14"></a><p></p>
<h1>16 HOW SUPPLIED/STORAGE AND HANDLING</h1>
<br><p class="First">Rizatriptan Benzoate Orally Disintegrating Tablets are available in strengths of 5 mg and 10 mg containing 7.265 mg or 14.53 mg of rizatriptan benzoate, USP equivalent to 5 mg or 10 mg of rizatriptan, respectively.</p>
<p>The 5 mg tablets are   white to off-white, round shaped uncoated tablets debossed with 'L58' on one side and plain on other side.</p>
<p>They are available as follows:<br>NDC 33342-093-48 PVC/PE/PVDC <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">blister</span> card of 10 tablets per triple laminated pouch, <br>                                    4 Triple laminated pouches per carton (40 tablets total).<br>NDC 33342-093-07  Container pack 30 tablets<br>NDC 33342-093-46  Container pack of 200 tablets<br>NDC 33342-093-12 Unit Dose <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">Blister</span> Package 100 (10×10)<br>NDC 33342-093-52 Unit Dose <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">Blister</span> Package 3 (1×3)<br>NDC 33342-093-73 Unit Dose <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">Blister</span> Package 9 (3×3)<br>NDC 33342-093-72 Unit Dose <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">Blister</span> Package 18 (6×3)<br>The 10 mg tablets are white to off-white, round shaped uncoated tablets debossed with 'L59' on one side and plain on other side.</p>
<p>They are available as follows:</p>
<p>NDC 33342-094-47 PVC/PE/PVDC <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">blister</span> card of 5 tablets per triple laminated pouch, <br>                                    4 Triple laminated pouches per carton (20 tablets total).<br>NDC 33342-094-07 Container pack 30 tablets<br>NDC 33342-094-46 Container pack of 200 tablets<br>NDC 33342-094-12 Unit Dose <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">Blister</span> Package 100 (10×10)<br>NDC 33342-094-52 Unit Dose <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">Blister</span> Package 3 (1×3)<br>NDC 33342-094-73 Unit Dose <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">Blister</span> Package 9 (3×3)<br>NDC 33342-094-72 Unit Dose <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">Blister</span> Package 18 (6×3)<br><span class="Bold">Store at 20º to 25ºC (68º to 77ºF). [See USP Controlled Room Temperature.]</span></p>
<br>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="Section_16"></a><a name="section-15"></a><p></p>
<h1>17 PATIENT COUNSELING INFORMATION</h1>
<p class="First"><span class="Italics">See FDA-Approved Patient Labeling (Patient Information).</span></p>
<br><p><span class="Bold">Risk of <span class="product-label-link" type="condition" conceptid="4124683" conceptname="Silent myocardial ischemia">Myocardial Ischemia</span> and/or <span class="product-label-link" type="condition" conceptid="4206471" conceptname="Infarct">Infarction</span>, Prinzmetal's Angina, Other <span class="product-label-link" type="condition" conceptid="4215494" conceptname="Vasospasm">Vasospasm</span>-related Events, and Cerebrovascular Events: </span>Inform patients that rizatriptan benzoate may cause serious cardiovascular side effects such as <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span> or <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span>. Although serious cardiovascular events can occur without warning symptoms, patients should be alert for the signs and symptoms of <span class="product-label-link" type="condition" conceptid="77670" conceptname="Chest pain">chest pain</span>, <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">shortness of breath</span>, <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">weakness</span>, slurring of speech, and should ask for medical advice when observing any indicative sign or symptoms. Patients should be apprised of the importance of this follow-up <span class="Italics">[see Warnings and Precautions (<a href="#Section_5.1">5.1</a>, <a href="#Section_5.2">5.2</a>, <a href="#Section_5.4">5.4</a>, <a href="#Section_5.5">5.5</a>)]</span>.</p>
<br><p><span class="Bold"><span class="product-label-link" type="condition" conceptid="4154707" conceptname="Serotonin syndrome">Serotonin Syndrome</span>: </span>Patients should be cautioned about the risk of <span class="product-label-link" type="condition" conceptid="4154707" conceptname="Serotonin syndrome">serotonin syndrome</span> with the use of rizatriptan benzoate or other triptans, particularly during combined use with selective serotonin reuptake inhibitors (SSRIs) or serotonin norepinephrine reuptake inhibitors (SNRIs) <span class="Italics">[see Warnings and Precautions (<a href="#Section_5.7">5.7</a>), Drug Interactions (<a href="#Section_7.4">7.4</a>), and Clinical Pharmacology (<a href="#Section_12.3">12.3</a>)]</span>. </p>
<br><p><span class="Bold">Pregnancy: </span>Inform patients that rizatriptan benzoate should not be used during pregnancy unless the potential benefit justifies the potential risk to the fetus <span class="Italics">[see Use in Specific Populations (<a href="#Section_8.1">8.1</a>)]</span>. </p>
<br><p><span class="Bold">Nursing Mothers: </span>Advise patients to notify their healthcare provider if they are breast-feeding or plan to breast-feed <span class="Italics">[see Use in Specific Populations (<a href="#Section_8.3">8.3</a>)]</span>. </p>
<br><p><span class="Bold">Ability to Perform Complex Tasks: </span>Since <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraines</span> or treatment with rizatriptan benzoate  may cause <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">somnolence</span> and <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, instruct patients to evaluate their ability to perform complex tasks during <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraine</span> attacks and after administration of rizatriptan benzoate.</p>
<br><p><span class="Bold">Medication Overuse <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headache</span>: </span>Inform patients that use of <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">acute migraine</span> drugs for 10 or more days per month may lead to an exacerbation of <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, and encourage patients to record <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span> frequency and drug use (e.g., by keeping a <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span> diary) <span class="Italics">[see Warnings and Precautions (<a href="#Section_5.6">5.6</a>)]</span>. </p>
<br><p><span class="Bold">Handling of Orally Disintegrating Tablets:</span> Instruct patients not to remove the <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">blister</span> from the carton until ready to use the orally disintegrating tablet inside <span class="Italics">[see Dosage and Administration (<a href="#Section_2.4">2.3</a>)].</span></p>
<p><span class="Bold">Patients with <span class="product-label-link" type="condition" conceptid="432872" conceptname="Phenylketonuria">Phenylketonuria</span>:</span> Inform phenylketonuric patients that rizatriptan benzoate orally disintegrating tablets contain phenylalanine (a component of aspartame). Each 5 mg orally disintegrating tablet contains 0.84 mg phenylalanine, and each 10 mg orally disintegrating tablet contains 1.68 mg phenylalanine <span class="Italics">[see Use in Specific Populations (<a href="#Section_8.6">8.6</a>)]</span>.</p>
<p>Manufactured for:</p>
<br><p><span class="Bold">Macleods Pharma USA, Inc.</span></p>
<p>Plainsboro, NJ 08536</p>
<p><span class="Bold">Manufactured by:</span></p>
<br><p><span class="Bold">Macleods Pharmaceutical Ltd.</span></p>
<p>Baddi, Himachal Pradesh, INDIA</p>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_16.1"></a><a name="section-15.1"></a><p></p>
<p class="First">.</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Unclassified_Section_27"></a><a name="section-16"></a><p></p>
<h1>SPL PATIENT PACKAGE INSERT SECTION</h1>
<p class="First">.</p>
<p><span class="Bold">RIZATRIPTAN BENZOATE ORALLY DISINTEGRATING TABLETS</span></p>
<p><span class="Bold">5 mg and 10 mg</span></p>
<br><p>Read this Patient Information before you start taking rizatriptan benzoate and each time you get a refill. There may be new information. This information does not take the place of talking to your doctor about your medical condition or your treatment.</p>
<p><span class="Bold">What is rizatriptan benzoate tablet?</span></p>
<p>Rizatriptan benzoate orally disintegrating tablet is a prescription medicine that belongs to a class of medicines called Triptans. </p>
<br><p>Rizatriptan benzoate is available as a traditional tablet                  </p>
<br><p>Rizatriptan benzoate orally disintegrating tablets are used to treat <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraine</span> attacks with or without <span class="product-label-link" type="condition" conceptid="4091160" conceptname="Aura">aura</span> in adults.</p>
<br><p>Rizatriptan benzoate  is not to be used to prevent <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraine</span> attacks.</p>
<br><p>Rizatriptan benzoate orally disintegrating tablet is not for the treatment of hemiplegic or basilar <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraines</span>.</p>
<br><p>It is not known if rizatriptan benzoate orally disintegrating tablet is safe and effective for the treatment of <span class="product-label-link" type="condition" conceptid="381278" conceptname="Cluster headache">cluster headaches</span>.</p>
<br><p>It is not known if rizatriptan benzoate orally disintegrating tablet is safe and effective in children under 6 years of age.</p>
<br><p><span class="Bold">Who should not take rizatriptan benzoate orally disintegrating tablets? </span></p>
<p><span class="Bold">Do not take rizatriptan benzoate orally disintegrating tablets if you:</span></p>
<ul class="Disc">
<li>have or have had heart problems</li>
<li>have or have had a <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span> or a transient ischemic attack (TIA)</li>
<li>have or have had blood vessel problems including ischemic bowel disease</li>
<li>have uncontrolled high blood pressure</li>
<li>have taken other Triptan medicines in the last 24 hours</li>
<li>have taken ergot-containing medicines in the last 24 hours</li>
<li>have hemiplegic or basilar <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraines</span></li>
<li>take monoamine oxidase (MAO) inhibitor or have taken a MAO inhibitor within the last 2 weeks</li>
<li>are allergic to rizatriptan benzoate or any of the ingredients in rizatriptan benzoate orally disintegrating tablets. See the end of this leaflet for a complete list of ingredients in rizatriptan benzoate orally disintegrating tablets.</li>
</ul>
<br><p>Talk to your doctor before taking this medicine if you have any of the conditions listed above or if you are not sure if you take any of these medicines.</p>
<br><p><span class="Bold">What should I tell my doctor before taking rizatriptan benzoate orally disintegrating tablets? </span></p>
<p><span class="Bold">Before you take rizatriptan orally disintegrating benzoate tablets</span>, tell your doctor if you:</p>
<ul class="Disc">
<li>have or have had heart problems, high blood pressure, <span class="product-label-link" type="condition" conceptid="77670" conceptname="Chest pain">chest pain</span>, or <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">shortness of breath</span></li>
<li>have any risk factors for heart problems or blood vessel problems such as:    <ul class="Disc">
<li>high blood pressure</li>
<li>high <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span></li>
<li>smoking</li>
<li><span class="product-label-link" type="condition" conceptid="433736" conceptname="Obesity">obesity</span></li>
<li><span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span></li>
<li>family history of heart problems</li>
<li>you are post menopausal</li>
<li>you are a male over 40</li>
</ul>
</li>
</ul>
<br><p>?  have <span class="product-label-link" type="condition" conceptid="432872" conceptname="Phenylketonuria">phenylketonuria</span> (PKU). Rizatriptan benzoate orally disintegrating tablets contain <br>       phenylalanine.</p>
<ul class="Disc">
<li>have kidney or liver problems </li>
<li>have any other medical condition </li>
<li>are pregnant or plan to become pregnant. It is not known if rizatriptan benzoate orally disintegrating tablets will harm your unborn baby. If you become pregnant while taking rizatriptan benzoate orally disintegrating tablets, talk to your healthcare provider. </li>
<li>are breast-feeding or plan to breast-feed. It is not known if rizatriptan benzoate passes into your breast milk. Talk to your doctor about the best way to feed your baby if you take rizatriptan benzoate orally disintegrating tablets.</li>
</ul>
<br><p><span class="Bold">Tell your doctor about all the medicines you take</span>, including prescription and nonprescription medicines, vitamins, and herbal supplements.</p>
<br><p>Rizatriptan benzoate orally disintegrating tablets and other medicines may affect each other causing side effects. Rizatriptan benzoate orally disintegrating tablets may affect the way other medicines work, and other medicines may affect how rizatriptan benzoate orally disintegrating tablets work.</p>
<br><p><span class="Bold">Especially tell your doctor if you take:</span></p>
<ul class="Disc">
<li>propranolol containing medicines such as Inderal<span class="Sup">®*</span>, Inderal<span class="Sup">®</span> LA<span class="Sup">*</span>, or Innopran<span class="Sup">®</span> XL<span class="Sup">*</span>
</li>
<li>medicines used to treat mood disorders, including selective serotonin reuptake inhibitors (SSRIs) or serotonin norepinephrine reuptake inhibitors (SNRIs).</li>
</ul>
<br><p>Ask your doctor or pharmacist for a list of these medicines, if you are not sure.</p>
<br><p>Know the medicines you take. Keep a list of them to show your doctor and pharmacist when you get a new medicine.</p>
<br><p><span class="Bold">How should I take rizatriptan benzoate orally disintegrating tablets?</span></p>
<ul class="Disc">
<li>Take rizatriptan benzoate tablets exactly as your doctor tells you to take it. </li>
<li>Your doctor will tell you how much rizatriptan benzoate to take and when to take it.</li>
<li>
<span class="Bold">To take</span> rizatriptan benzoate orally disintegrating tablets: <ul class="Disc">
<li>Leave rizatriptan benzoate orally disintegrating tablets in the package it comes in until you are ready to take it. </li>
<li>Remove the <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">blister</span> from the carton. Do not push the rizatriptan benzoate orally disintegrating tablet through the <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">blister</span>.</li>
<li>Peel open the <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">blister</span> pack with dry hands and place the rizatriptan benzoate orally disintegrating tablet on your tongue. The tablet will dissolve and be swallowed with your saliva. No liquid is needed to take the orally disintegrating tablet.</li>
</ul>
</li>
<li>If your <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span> comes back after your first rizatriptan benzoate tablets dose:    <ul class="Disc"><li>For adults: a second dose may be taken 2 hours after the first dose. Do not take more than 30 mg of rizatriptan benzoate tablets in a 24-hour period (for example, do not take more than three 10 mg tablets in a 24-hour period).</li></ul>
</li>
</ul>
<br><ul class="Disc"><li>If you take too much rizatriptan benzoate, call your doctor or go to the nearest hospital emergency room right away.</li></ul>
<br><p><span class="Bold">What should I avoid while taking rizatriptan benzoate orally disintegrating tablets?</span></p>
<p>Rizatriptan benzoate orally disintegrating tablets may cause <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">weakness</span>, or <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">fainting</span>. If you have these symptoms, do not drive a car, use machinery, or do anything that needs you to be alert.</p>
<br><p><span class="Bold">What are the possible side effects of rizatriptan benzoate orally disintegrating tablets?</span></p>
<p><span class="Bold">Rizatriptan benzoate orally disintegrating tablets may cause serious side effects.</span> Call your doctor or go to the nearest hospital emergency room right away if you think you are having any of the serious side effects of rizatriptan benzoate orally disintegrating tablets including:</p>
<br><ul class="Disc"><li>
<span class="Bold"><span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">heart attack</span>.</span> Symptoms of a <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">heart attack</span> may include:    <ul class="Disc">
<li><span class="product-label-link" type="condition" conceptid="4133044" conceptname="Chest discomfort">chest discomfort</span> in the center of your chest that lasts for more than a few minutes or that goes away and comes back</li>
<li><span class="product-label-link" type="condition" conceptid="4133044" conceptname="Chest discomfort">chest discomfort</span> that feels like uncomfortable pressure, squeezing, fullness or <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span></li>
<li><span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> or <span class="product-label-link" type="condition" conceptid="4090431" conceptname="Discomfort">discomfort</span> in your arms, back, neck, jaw or stomach</li>
<li><span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">shortness of breath</span> with or without <span class="product-label-link" type="condition" conceptid="4133044" conceptname="Chest discomfort">chest discomfort</span></li>
<li>breaking out in a <span class="product-label-link" type="condition" conceptid="4308436" conceptname="Cold sweat">cold sweat</span></li>
<li><span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> or <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span></li>
<li>feeling lightheaded</li>
</ul>
</li></ul>
<br><ul class="Disc"><li>
<span class="Bold"><span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span>.</span> Symptoms of a <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span> may include the following sudden symptoms:    <ul class="Disc">
<li><span class="product-label-link" type="condition" conceptid="4151171" conceptname="Numbness of limbs">numbness</span> or <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">weakness</span> in your face, arm or leg, especially on one side of your body</li>
<li><span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">confusion</span>, problems speaking or understanding</li>
<li>problems seeing in one or both of your eyes</li>
<li>problems walking, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, loss of balance or coordination</li>
<li>severe <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span> with no known cause</li>
</ul>
</li></ul>
<br><ul class="Disc"><li>
<span class="Bold">blood vessel problems.</span> Symptoms of blood vessel problems may include:    <ul class="Disc">
<li><span class="product-label-link" type="condition" conceptid="194175" conceptname="Left upper quadrant pain">stomach pain</span></li>
<li><span class="product-label-link" type="condition" conceptid="4318833" conceptname="Hemorrhagic diarrhea">bloody diarrhea</span></li>
<li>vision problems</li>
<li><span class="product-label-link" type="condition" conceptid="4276665" conceptname="Feels cold">coldness</span> and <span class="product-label-link" type="condition" conceptid="4151171" conceptname="Numbness of limbs">numbness</span> of hands and feet</li>
</ul>
</li></ul>
<br><ul class="Disc"><li>
<span class="Bold"><span class="product-label-link" type="condition" conceptid="4154707" conceptname="Serotonin syndrome">serotonin syndrome</span>.</span> A condition called <span class="product-label-link" type="condition" conceptid="4154707" conceptname="Serotonin syndrome">serotonin syndrome</span> can happen when Triptan medicines such as rizatriptan benzoate tablets are taken with certain other medicines. Symptoms of <span class="product-label-link" type="condition" conceptid="4154707" conceptname="Serotonin syndrome">serotonin syndrome</span> may include:    <ul class="Disc">
<li><span class="product-label-link" type="condition" conceptid="436087" conceptname="Excitement">agitation</span></li>
<li><span class="product-label-link" type="condition" conceptid="433031" conceptname="Hallucinations">hallucinations</span></li>
<li><span class="product-label-link" type="condition" conceptid="380834" conceptname="Coma">coma</span></li>
<li>fast heartbeat</li>
<li>fast changes in your blood pressure</li>
<li>increased body temperature</li>
<li><span class="product-label-link" type="condition" conceptid="75635" conceptname="Cramp">muscle spasm</span></li>
<li>loss of coordination</li>
<li><span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> or <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span></li>
</ul>
</li></ul>
<br><ul class="Disc"><li><span class="Bold"><span class="product-label-link" type="condition" conceptid="141693" conceptname="Elevated blood-pressure reading without diagnosis of hypertension">increased blood pressure</span></span></li></ul>
<br><p>The most common side effects of rizatriptan benzoate orally disintegrating tablets in adults include:</p>
<ul class="Disc">
<li>feeling <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">sleepy</span> or tired</li>
<li><span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> or pressure in your chest or throat</li>
<li><span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span></li>
</ul>
<br><p>Tell your doctor if you have any side effect that bothers you or that does not go away.</p>
<br><p>If you take rizatriptan benzoate orally disintegrating tablets too often, this may result in you getting <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">chronic headaches</span>. In such cases, you should contact your doctor, as you may have to stop taking rizatriptan benzoate orally disintegrating tablets.</p>
<br><p>These are not all the possible side effects of rizatriptan benzoate orally disintegrating tablets. For more information, ask your doctor or pharmacist.</p>
<br><p><span class="Bold">Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.</span></p>
<br><p><span class="Bold">How should I store rizatriptan benzoate orally disintegrating tablets?</span></p>
<ul class="Disc">
<li>Store rizatriptan benzoate tablets between 20º to 25ºC (68º to 77ºF). </li>
<li>Safely throw away medicine that is out of date or no longer needed.</li>
</ul>
<br><p><span class="Bold">Keep rizatriptan benzoate tablets and all medicines out of the reach of children.</span></p>
<br><p><span class="Bold">General Information About the Safe and Effective Use of Rizatriptan Benzoate Orally Disintegrating Tablets.</span></p>
<p>Medicines are sometimes prescribed for purposes other than those listed in a Patient Information leaflet. Do not use rizatriptan benzoate for a condition for which it was not prescribed. Do not give rizatriptan benzoate tablets to other people, even if they have the same symptoms that you have. It may harm them.</p>
<br><p>This Patient Information leaflet summarizes the most important information about rizatriptan benzoate orally disintegrating tablets. If you would like more information, talk to your doctor. You can ask your pharmacist or doctor for information about rizatriptan benzoate orally disintegrating tablets that is written for health professionals.</p>
<br><p>For more information, call  Macleods Pharma USA, Inc at1-888-943-3210.</p>
<br><p><span class="Bold">What are the ingredients in rizatriptan benzoate orally disintegrating tablets?</span></p>
<p><span class="Bold">Active ingredient: </span>rizatriptan benzoate, USP.</p>
<br><p><span class="Bold">Inactive ingredients in rizatriptan benzoate orally disintegrating tablets:</span></p>
<br><p>microcrystalline cellulose, colloidal silicon dioxide, carboxymethyl cellulose calcium, magnesium stearate, mannitol, aspartame, and peppermint flavor.</p>
<p><span class="Bold">Phenylketonurics: </span></p>
<p>Rizatriptan benzoate orally disintegrating tablets 5 mg contain 0.84 mg of phenylalanine. Rizatriptan benzoate orally disintegrating tablets 10 mg contain 1.68 mg of phenylalanine. </p>
<br><p><span class="Italics">Information related to the usage of rizatriptan benzoate orally disintegrating tablets for pediatric patients aged 6 to 17 years is approved for Merck &amp; Co., Inc.’s Rizatriptan Benzoate Orally Disintegrating Tablets. However, due to Merck &amp; Co., Inc.’s marketing exclusivity rights, this drug product is not labeled with that information.</span></p>
<br><p><span class="Sup">®*</span> The brand names mentioned are registered trademarks of their respective manufacturers.</p>
<br><p>This Patient Information has been approved by the U.S. Food and Drug Administration.</p>
<br><br><br><p>Manufactured for:</p>
<br><p><span class="Bold">Macleods Pharma USA, Inc.</span></p>
<p>Plainsboro, NJ 08536</p>
<p><span class="Bold">Manufactured by:</span></p>
<br><p><span class="Bold">Macleods Pharmaceutical Ltd.</span></p>
<p>Baddi, Himachal Pradesh, INDIA<br>Revised 07/2015                                                                                                                                                                                                                                                                                              <br><br>                                                                                                                                                                                                                                                                                                                                PM01750201</p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="Section_18"></a><a name="section-17"></a><p></p>
<h1>PACKAGE LABEL.PRINCIPAL DISPLAY PANEL</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_18.1"></a><a name="section-17.1"></a><p></p>
<p class="First">Rx Only<br>NDC 33342-093-07<br>Rizatriptan Benzoate Orally Disintegrating Tablets <br>5 mg <br>Bottle of 30 tablets</p>
<br><br><div class="Figure"><img alt="Bottle-of-30-tablets" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=57ed2505-28f1-4292-b3c3-a49bf0f7c683&amp;name=rizatriptan-5mg-30s-bottle.jpg"></div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_18.2"></a><a name="section-17.2"></a><p></p>
<p class="First">Rx Only<br>NDC 33342-093-46<br>Rizatriptan Benzoate Orally Disintegrating Tablets <br>5 mg <br>Bottle of 200 tablets</p>
<br><br><div class="Figure"><img alt="Bottle-of-200-tablets" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=57ed2505-28f1-4292-b3c3-a49bf0f7c683&amp;name=rizatriptan-5mg-200s-bottle.jpg"></div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_18.3"></a><a name="section-17.3"></a><p></p>
<p class="First">Rx Only<br>NDC 33342-093-12<br>Rizatriptan Benzoate Orally Disintegrating Tablets <br>5 mg <br>Carton of 100 (10x10 unit dose tablets)</p>
<br><br><div class="Figure"><img alt="Carton-of-100" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=57ed2505-28f1-4292-b3c3-a49bf0f7c683&amp;name=rizatriptan-5mg-100s-carton.jpg"></div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_18.4"></a><a name="section-17.4"></a><p></p>
<p class="First">Rx Only<br>NDC 33342-093-48<br>Rizatriptan Benzoate Orally Disintegrating Tablets <br>5 mg <br>Carton of  40 (4x10 unit dose tablets)</p>
<br><br><div class="Figure"><img alt="Carton-of-40" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=57ed2505-28f1-4292-b3c3-a49bf0f7c683&amp;name=rizatriptan-5mg-40s-carton.jpg"></div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_18.5"></a><a name="section-17.5"></a><p></p>
<p class="First">Rx Only<br>NDC 33342-094-07<br>Rizatriptan Benzoate Orally Disintegrating Tablets <br>10 mg <br>Bottle of 30 tablets</p>
<br><div class="Figure"><img alt="Bottle-of-30-tablets" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=57ed2505-28f1-4292-b3c3-a49bf0f7c683&amp;name=rizatriptan-10mg-30s-bottle.jpg"></div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_18.6"></a><a name="section-17.6"></a><p></p>
<p class="First">Rx Only<br>NDC 33342-094-46<br>Rizatriptan Benzoate Orally Disintegrating Tablets <br>10 mg <br>Bottle of 200 tablets</p>
<br><br><div class="Figure"><img alt="Bottle-of-200-tablets" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=57ed2505-28f1-4292-b3c3-a49bf0f7c683&amp;name=rizatriptan-10mg-200s-bottle.jpg"></div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_18.7"></a><a name="section-17.7"></a><p></p>
<p class="First">Rx Only<br>NDC 33342-094-12<br>Rizatriptan Benzoate Orally Disintegrating Tablets <br>10 mg <br>Carton of 100 (10x10unit dose tablets)</p>
<br><br><div class="Figure"><img alt="Carton-of-100" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=57ed2505-28f1-4292-b3c3-a49bf0f7c683&amp;name=rizatriptan-10mg-100s-cartons.jpg"></div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_18.8"></a><a name="section-17.8"></a><p></p>
<p class="First">Rx Only<br>NDC 33342-094-47<br>Rizatriptan Benzoate Orally Disintegrating Tablets <br>10 mg <br>Carton of 20 (4x5 unit dose tablets)</p>
<br><br><div class="Figure"><img alt="Carton-of-20" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=57ed2505-28f1-4292-b3c3-a49bf0f7c683&amp;name=rizatriptan-10mg-20s-carton.jpg"></div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_18.9"></a><a name="section-17.9"></a><p></p>
<p class="First">Rx Only<br>NDC 33342-093-52<br>Rizatriptan Benzoate Orally Disintegrating Tablets <br>5 mg <br>Carton of 3 (1x3 unit dose tablets)</p>
<br><div class="Figure"><img alt="carton-5mg-3tab" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=57ed2505-28f1-4292-b3c3-a49bf0f7c683&amp;name=carton-5mg-3tab.jpg"></div>
<br><p>Rx Only<br>NDC 33342-093-73<br>Rizatriptan Benzoate Orally Disintegrating Tablets <br>5 mg <br>Carton of 9 (3x3 unit dose tablets)</p>
<br><div class="Figure"><img alt="carton-5mg-9tab" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=57ed2505-28f1-4292-b3c3-a49bf0f7c683&amp;name=carton-5mg-9tab.jpg"></div>
<br><p>Rx Only<br>NDC 33342-093-72<br>Rizatriptan Benzoate Orally Disintegrating Tablets <br>5 mg <br>Carton of 18 (6x3 unit dose tablets)</p>
<br><div class="Figure"><img alt="carton-5mg-18tab" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=57ed2505-28f1-4292-b3c3-a49bf0f7c683&amp;name=carton-5mg-18tab.jpg"></div>
<br><p>Rx Only<br>NDC 33342-094-52<br>Rizatriptan Benzoate Orally Disintegrating Tablets 10<br>mg <br>Carton of 3 (1x3 unit dose tablets)</p>
<br><div class="Figure"><img alt="carton-10mg-3tab" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=57ed2505-28f1-4292-b3c3-a49bf0f7c683&amp;name=carton-10mg-3tab.jpg"></div>
<br><p>Rx Only<br>NDC 33342-094-73<br>Rizatriptan Benzoate Orally Disintegrating Tablets 10<br>mg <br>Carton of 9 (3x3 unit dose tablets)</p>
<br><div class="Figure"><img alt="carton-10mg-9tab" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=57ed2505-28f1-4292-b3c3-a49bf0f7c683&amp;name=carton-10mg-9tab.jpg"></div>
<br><p>Rx Only<br>NDC 33342-094-72<br>Rizatriptan Benzoate Orally Disintegrating Tablets 10<br>mg <br>Carton of 18 (6x3 unit dose tablets)</p>
<br><div class="Figure"><img alt="carton-10mg-18tab" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=57ed2505-28f1-4292-b3c3-a49bf0f7c683&amp;name=carton-10mg-18tab.jpg"></div>
</div>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>RIZATRIPTAN BENZOATE 		
					</strong><br><span class="contentTableReg">rizatriptan benzoate tablet, orally disintegrating</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:33342-093</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>RIZATRIPTAN BENZOATE</strong> (RIZATRIPTAN) </td>
<td class="formItem">RIZATRIPTAN</td>
<td class="formItem">5 mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>CELLULOSE, MICROCRYSTALLINE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>COLLOIDAL SILICON DIOXIDE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>CARBOXYMETHYLCELLULOSE CALCIUM</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>MAGNESIUM STEARATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>MANNITOL</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>ASPARTAME</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>PEPPERMINT</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">WHITE (white to off white) </td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">ROUND (round) </td>
<td class="formLabel">Size</td>
<td class="formItem">7mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">L58</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:33342-093-48</td>
<td class="formItem">4  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem"></td>
<td class="formItem">1  in 1 POUCH</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem"></td>
<td class="formItem">10  in 1 <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">BLISTER</span> PACK; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">2</th>
<td class="formItem">NDC:33342-093-07</td>
<td class="formItem">30  in 1 CONTAINER; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">3</th>
<td class="formItem">NDC:33342-093-46</td>
<td class="formItem">200  in 1 CONTAINER; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">4</th>
<td class="formItem">NDC:33342-093-12</td>
<td class="formItem">10  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">4</th>
<td class="formItem"></td>
<td class="formItem">10  in 1 <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">BLISTER</span> PACK; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">5</th>
<td class="formItem">NDC:33342-093-52</td>
<td class="formItem">1  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">5</th>
<td class="formItem"></td>
<td class="formItem">3  in 1 <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">BLISTER</span> PACK; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">6</th>
<td class="formItem">NDC:33342-093-73</td>
<td class="formItem">3  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">6</th>
<td class="formItem"></td>
<td class="formItem">3  in 1 <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">BLISTER</span> PACK; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">7</th>
<td class="formItem">NDC:33342-093-72</td>
<td class="formItem">6  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">7</th>
<td class="formItem"></td>
<td class="formItem">3  in 1 <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">BLISTER</span> PACK; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">ANDA</td>
<td class="formItem">ANDA203146</td>
<td class="formItem">09/23/2014</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>RIZATRIPTAN BENZOATE 		
					</strong><br><span class="contentTableReg">rizatriptan benzoate tablet, orally disintegrating</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:33342-094</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>RIZATRIPTAN BENZOATE</strong> (RIZATRIPTAN) </td>
<td class="formItem">RIZATRIPTAN</td>
<td class="formItem">10 mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>CELLULOSE, MICROCRYSTALLINE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>COLLOIDAL SILICON DIOXIDE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>CARBOXYMETHYLCELLULOSE CALCIUM</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>MAGNESIUM STEARATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>MANNITOL</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>ASPARTAME</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>PEPPERMINT</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">WHITE (white to off white) </td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">ROUND (round) </td>
<td class="formLabel">Size</td>
<td class="formItem">9mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">L59</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:33342-094-47</td>
<td class="formItem">4  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem"></td>
<td class="formItem">1  in 1 POUCH</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem"></td>
<td class="formItem">5  in 1 <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">BLISTER</span> PACK; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">2</th>
<td class="formItem">NDC:33342-094-07</td>
<td class="formItem">30  in 1 CONTAINER; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">3</th>
<td class="formItem">NDC:33342-094-46</td>
<td class="formItem">200  in 1 CONTAINER; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">4</th>
<td class="formItem">NDC:33342-094-12</td>
<td class="formItem">10  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">4</th>
<td class="formItem"></td>
<td class="formItem">10  in 1 <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">BLISTER</span> PACK; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">5</th>
<td class="formItem">NDC:33342-094-52</td>
<td class="formItem">1  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">5</th>
<td class="formItem"></td>
<td class="formItem">3  in 1 <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">BLISTER</span> PACK; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">6</th>
<td class="formItem">NDC:33342-094-73</td>
<td class="formItem">3  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">6</th>
<td class="formItem"></td>
<td class="formItem">3  in 1 <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">BLISTER</span> PACK; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">7</th>
<td class="formItem">NDC:33342-094-72</td>
<td class="formItem">6  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">7</th>
<td class="formItem"></td>
<td class="formItem">3  in 1 <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">BLISTER</span> PACK; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">ANDA</td>
<td class="formItem">ANDA203146</td>
<td class="formItem">09/23/2014</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>Macleods Pharmaceuticals Limited
							(862128535)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Macleods Pharmaceuticals Limited</td>
<td class="formItem"></td>
<td class="formItem">676369519</td>
<td class="formItem">ANALYSIS(33342-093, 33342-094), LABEL(33342-093, 33342-094), MANUFACTURE(33342-093, 33342-094), PACK(33342-093, 33342-094)</td>
</tr>
</table>
</div>
<p><div class="EffectiveDate">Revised: 7/2015<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>7ec20bbc-1652-4132-a6b9-28a1289439d0</div>
<div>Set id: 57ed2505-28f1-4292-b3c3-a49bf0f7c683</div>
<div>Version: 2</div>
<div>Effective Time: 20150710</div>
</div>
</div> <div class="DistributorName">Macleods Pharmaceuticals Limited</div></p>
</body></html>
